<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.0.38">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">

<meta name="description" content="eBook Companion for Audible Bleeding Podcast Series">

<title>Vascular Surgery Exam Prep - 15&nbsp; PAD Pathogenesis and Claudication</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<link href="./clti.html" rel="next">
<link href="./trauma-venous.html" rel="prev">
<link href="./images/ab_examprep_icon.png" rel="icon" type="image/png">
<script src="site_libs/cookie-consent/cookie-consent.js"></script>
<link href="site_libs/cookie-consent/cookie-consent.css" rel="stylesheet">
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "sidebar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "start",
  "type": "textbox",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit"
  }
}</script>
<script async="" src="https://www.googletagmanager.com/gtag/js?id=G-T4DWNE55D1"></script>

<script type="text/plain" cookie-consent="tracking">

window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'G-T4DWNE55D1', { 'anonymize_ip': true});
</script>

<script type="text/javascript" charset="UTF-8">
document.addEventListener('DOMContentLoaded', function () {
cookieconsent.run({
  "notice_banner_type":"simple",
  "consent_type":"implied",
  "palette":"light",
  "language":"en",
  "page_load_consent_levels":["strictly-necessary","functionality","tracking","targeting"],
  "notice_banner_reject_button_hide":false,
  "preferences_center_close_button_hide":false,
  "website_name":""
  });
});
</script> 
  
<script async="" src="https://hypothes.is/embed.js"></script>


<meta property="og:title" content="Vascular Surgery Exam Prep - 15&nbsp; PAD Pathogenesis and Claudication">
<meta property="og:description" content="eBook Companion for Audible Bleeding Podcast Series">
<meta property="og:site-name" content="Vascular Surgery Exam Prep">
<meta name="twitter:title" content="Vascular Surgery Exam Prep - 15&nbsp; PAD Pathogenesis and Claudication">
<meta name="twitter:description" content="eBook Companion for Audible Bleeding Podcast Series">
<meta name="twitter:card" content="summary">
</head>

<body class="nav-sidebar floating">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
  <nav class="quarto-secondary-nav" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar" aria-controls="quarto-sidebar" aria-expanded="false" aria-label="Toggle sidebar navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
    <div class="container-fluid d-flex justify-content-between">
      <h1 class="quarto-secondary-nav-title"><span class="chapter-number">15</span>&nbsp; <span class="chapter-title">PAD Pathogenesis and Claudication</span></h1>
      <button type="button" class="quarto-btn-toggle btn" aria-label="Show secondary navigation">
        <i class="bi bi-chevron-right"></i>
      </button>
    </div>
  </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article">
<!-- sidebar -->
  <nav id="quarto-sidebar" class="sidebar collapse sidebar-navigation floating overflow-auto">
    <div class="pt-lg-2 mt-2 text-left sidebar-header">
    <div class="sidebar-title mb-0 py-0">
      <a href="./">Vascular Surgery Exam Prep</a> 
        <div class="sidebar-tools-main">
    <a href="https://github.com/adam-mdmph/vs-examprep.git" title="Source Code" class="sidebar-tool px-1"><i class="bi bi-github"></i></a>
</div>
    </div>
      </div>
      <div class="mt-2 flex-shrink-0 align-items-center">
        <div class="sidebar-search">
        <div id="quarto-search" class="" title="Search"></div>
        </div>
      </div>
    <div class="sidebar-menu-container"> 
    <ul class="list-unstyled mt-1">
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./index.html" class="sidebar-item-text sidebar-link">Preface</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./authors.html" class="sidebar-item-text sidebar-link">Authors and Contributors</a>
  </div>
</li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" aria-expanded="true">Head and Neck</a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" aria-expanded="true">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-1" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./cerebrovascular.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">1</span>&nbsp; <span class="chapter-title">Cerebrovascular</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./trauma-cerebrovascular.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">2</span>&nbsp; <span class="chapter-title">Trauma - Cerebrovascular</span></a>
  </div>
</li>
      </ul>
  </li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-2" aria-expanded="true">Upper Extremity</a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-2" aria-expanded="true">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-2" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./upper-extremity.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">3</span>&nbsp; <span class="chapter-title">Upper Extremity</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./tos.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">4</span>&nbsp; <span class="chapter-title">Thoracic Outlet</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./hemodialysis.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">5</span>&nbsp; <span class="chapter-title">Hemodialysis</span></a>
  </div>
</li>
      </ul>
  </li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-3" aria-expanded="true">Thorax</a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-3" aria-expanded="true">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-3" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./dissection.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">6</span>&nbsp; <span class="chapter-title">Aortic Dissection</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./taaa.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">7</span>&nbsp; <span class="chapter-title">TAAA</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./aortopathies.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">8</span>&nbsp; <span class="chapter-title">Aortopathies</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./trauma-endovascular.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">9</span>&nbsp; <span class="chapter-title">Trauma - Endo</span></a>
  </div>
</li>
      </ul>
  </li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-4" aria-expanded="true">Abdomen</a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-4" aria-expanded="true">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-4" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./abdominal-aneurysms.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">10</span>&nbsp; <span class="chapter-title">AAA</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./mesenteric.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">11</span>&nbsp; <span class="chapter-title">Mesenteric Disease</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./renal.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">12</span>&nbsp; <span class="chapter-title">Renal</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./trauma-arterial.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">13</span>&nbsp; <span class="chapter-title">Trauma - Arterial</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./trauma-venous.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">14</span>&nbsp; <span class="chapter-title">Trauma - Venous</span></a>
  </div>
</li>
      </ul>
  </li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-5" aria-expanded="true">Lower Extremity</a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-5" aria-expanded="true">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-5" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./claudication.html" class="sidebar-item-text sidebar-link active"><span class="chapter-number">15</span>&nbsp; <span class="chapter-title">PAD Pathogenesis and Claudication</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./clti.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">16</span>&nbsp; <span class="chapter-title">CLTI</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./ali.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">17</span>&nbsp; <span class="chapter-title">Acute Limb Ischemia</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./venous-disease.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">18</span>&nbsp; <span class="chapter-title">Venous Disease</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./trauma-peripheral.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">19</span>&nbsp; <span class="chapter-title">Trauma - Peripheral</span></a>
  </div>
</li>
      </ul>
  </li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-6" aria-expanded="true">General</a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-6" aria-expanded="true">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-6" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./vascular-lab.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">20</span>&nbsp; <span class="chapter-title">Vascular Lab</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./endovascular.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">21</span>&nbsp; <span class="chapter-title">Endovascular</span></a>
  </div>
</li>
      </ul>
  </li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./references.html" class="sidebar-item-text sidebar-link">References</a>
  </div>
</li>
    </ul>
    </div>
</nav>
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc">
    <h2 id="toc-title">Table of contents</h2>
   
  <ul>
  <li><a href="#pathogenesis-of-peripheral-arterial-disease" id="toc-pathogenesis-of-peripheral-arterial-disease" class="nav-link active" data-scroll-target="#pathogenesis-of-peripheral-arterial-disease"> <span class="header-section-number">15.1</span> Pathogenesis of peripheral arterial disease</a></li>
  <li><a href="#intermittent-claudication" id="toc-intermittent-claudication" class="nav-link" data-scroll-target="#intermittent-claudication"> <span class="header-section-number">15.2</span> Intermittent Claudication</a>
  <ul class="collapse">
  <li><a href="#history-clinical-examination" id="toc-history-clinical-examination" class="nav-link" data-scroll-target="#history-clinical-examination"> <span class="header-section-number">15.2.1</span> History / Clinical Examination</a></li>
  <li><a href="#management" id="toc-management" class="nav-link" data-scroll-target="#management"> <span class="header-section-number">15.2.2</span> Management</a></li>
  </ul></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title d-none d-lg-block"><span class="chapter-number">15</span>&nbsp; <span class="chapter-title">PAD Pathogenesis and Claudication</span></h1>
</div>

<div>
  <div class="description">
    eBook Companion for Audible Bleeding Podcast Series
  </div>
</div>


<div class="quarto-title-meta">

    
    
  </div>
  

</header>

<p>Authors: <em>Nedal Katib and Danielle Bajakian</em></p>
<p>Contributors: <em>Eilidh Gunn</em></p>
<div class="cell">
<div class="cell-output-display">
<audio controls=""> <source src="https://traffic.libsyn.com/audiblebleeding/PAOD_part_1_postEQ.mp3" type="audio/mpeg"> Your browser does not support the audio tag;  for browser support, please see:  https://www.w3schools.com/tags/tag_audio.asp </audio>
</div>
</div>
<section id="pathogenesis-of-peripheral-arterial-disease" class="level2" data-number="15.1">
<h2 data-number="15.1" class="anchored" data-anchor-id="pathogenesis-of-peripheral-arterial-disease"><span class="header-section-number">15.1</span> Pathogenesis of peripheral arterial disease</h2>
<p><strong>What is Peripheral Artery Occlusive Disease (PAD)?</strong></p>
<p>Peripheral Arterial Disease encompasses extremity arterial disease but generally is used to describe lower limb arterial occlusive disease. Peripheral Artery Occlusive Disease (PAD) is a more specific term and this encompasses atherosclerotic disease of the lower limb arteries.</p>
<p>The disease has a step-wise spectrum of presentations from asymptomatic disease to intermittent claudication and finally chronic limb threatening ischemia (CLTI) formerly known as Critical Limb Ischemia (CLI) <span class="citation" data-cites="aboyans2017ESCGuidelines2018">(<a href="references.html#ref-aboyans2017ESCGuidelines2018" role="doc-biblioref">Aboyans et al. 2018</a>)</span></p>
<p><strong>What is the underlying pathophysiology of PAD?</strong></p>
<p>The understanding of the underlying pathophysiology which results in occlusive arterial disease of the lower limb has evolved over the last 50 years. Atherosclerosis remains the main pathological process resulting in occlusive disease with smoking being the primary modifiable risk factor.<br>
Although with the rising incidence of diabetes a second population of patients with a significant PAD burden has developed.</p>
<p>Atherosclerosis begins with an injury to the intimal lining of the arterial wall, which, for example, can result from smoking, hypertension, hyperglycemia, or advanced age. Repeated injury leads to a chronic inflammatory process resulting in the uptake and oxidation of LDL, resulting in foam cells.<span class="citation" data-cites="hiltunen1998 tsimikas2005 witztum1994">(<a href="references.html#ref-hiltunen1998" role="doc-biblioref">Hiltunen et al. 1998</a>; <a href="references.html#ref-tsimikas2005" role="doc-biblioref">Tsimikas et al. 2005</a>; <a href="references.html#ref-witztum1994" role="doc-biblioref">Witztum 1994</a>)</span> Foam cells result when unregulated scavenger receptors promote uptake of oxidized LDL by macrophages and smooth muscle cells. These foam cells become necrotic and then create the central core of the atheroma.<span class="citation" data-cites="owens2019">(<a href="references.html#ref-owens2019" role="doc-biblioref">Owens 2019</a>)</span> This oxidized LDL form into intimal plaque, build up and calcification that may result in progressive vessel stenosis and subsequent occlusion, or plaque rupture with acute occlusion.</p>
<p>Atherosclerosis is particularly prone to developing at sites of arterial bifurcation (i.e.&nbsp;carotid bifurcation, femoral bifurcation) because turbulent flow and low laminar shear stress results in the down regulation of eNOS and NO production. This in turn increases V-CAM-1 and reduces inhibition of KF-kB (resulting in it’s elevation.<span class="citation" data-cites="owens2019">(<a href="references.html#ref-owens2019" role="doc-biblioref">Owens 2019</a>)</span></p>
<table class="table">
<caption><strong>AHA lesion classification</strong> - defines plaque risk for rupture/thrombosis. Extrapolated from the coronary artery disease literature.<span class="citation" data-cites="mcgill2000">(<a href="references.html#ref-mcgill2000" role="doc-biblioref">McGill et al. 2000</a>)</span></caption>
<colgroup>
<col style="width: 33%">
<col style="width: 66%">
</colgroup>
<thead>
<tr class="header">
<th style="text-align: center;">Classification</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: center;">0</td>
<td>Normal artery</td>
</tr>
<tr class="even">
<td style="text-align: center;">1</td>
<td>Initial atherosclerotic lesion</td>
</tr>
<tr class="odd">
<td style="text-align: center;">2</td>
<td>Fatty streak</td>
</tr>
<tr class="even">
<td style="text-align: center;">3</td>
<td>Fatty plaque/raised fatty streak</td>
</tr>
<tr class="odd">
<td style="text-align: center;">4</td>
<td>Atheroma</td>
</tr>
<tr class="even">
<td style="text-align: center;">5</td>
<td>Fibroatheroma - development of fibrotic cap, vascularization or calcium</td>
</tr>
<tr class="odd">
<td style="text-align: center;">6</td>
<td>Complicated lesion</td>
</tr>
</tbody>
</table>
<p><strong>What are the risk factors for atherosclerosis?</strong></p>
<p><strong>Modifiable:</strong></p>
<ol type="1">
<li><p><strong><em>Smoking</em></strong></p>
<ul>
<li><p>The <strong>most significant modifiable risk factor</strong> for developing peripheral arterial disease.</p></li>
<li><p>Causes endothelial dysfunction by reducing nitric oxide and triggering reactive-oxygen species, platelet adhesion, and permeability of endothelial surface to fibrinogen.<span class="citation" data-cites="unitedstatessurgeongeneralHealthConsequencesSmoking2014 hackam2003">(<a href="references.html#ref-unitedstatessurgeongeneralHealthConsequencesSmoking2014" role="doc-biblioref">United States Surgeon General 2014</a>; <a href="references.html#ref-hackam2003" role="doc-biblioref">Hackam and Anand 2003</a>)</span>.</p></li>
<li><p>Causes a prothrombotic environment by causing an increase in thromboxane A2 and decreasing prostacyclin thus overall resulting in increased prothrombotic environment for platelets.</p></li>
<li><p>Smoking has a stronger association with Intermittent claudication than with Coronary Artery Disease! <span class="citation" data-cites="gordonPredispositionAtherosclerosisHead1972">(<a href="references.html#ref-gordonPredispositionAtherosclerosisHead1972" role="doc-biblioref">Gordon and Kannel 1972</a>)</span></p></li>
</ul></li>
<li><p><strong><em>Diabetes, Metabolic Syndrome, and Insulin Resistance</em></strong></p>
<ul>
<li><p>Diabetes Mellitus, after smoking, is the most significant modifiable risk factor for developing peripheral arterial disease. Both insulin resistance and hyperinsulinemia are independent risk factors for developing peripheral arterial disease.</p></li>
<li><p>The Odds Risk for developing PAD in patients with DM ranges from 1.89 to 4.05.</p></li>
<li><p>Factors associated with developing PAD in diabetics include female gender, chronicity/severity of DM, insulin dependence, African American race or Hispanic ethnicity.<span class="citation" data-cites="regensteiner2015 selvin2006 wattanakit2005">(<a href="references.html#ref-regensteiner2015" role="doc-biblioref">Regensteiner et al. 2015</a>; <a href="references.html#ref-selvin2006" role="doc-biblioref">Selvin et al. 2006</a>; <a href="references.html#ref-wattanakit2005" role="doc-biblioref">Wattanakit et al. 2005</a>)</span> An increase in HbA1C by 1% correlates with a 28% increase risk of developing PAD. <span class="citation" data-cites="adlerUKPDS59Hyperglycemia2002">(<a href="references.html#ref-adlerUKPDS59Hyperglycemia2002" role="doc-biblioref">Amanda I. Adler et al. 2002</a>)</span></p></li>
<li><p>The following mechanisms may lead to PAD in diabetics</p>
<ul>
<li><p>Hyperglycemia reduces bioavailability of NO, which is a vasodilator, enhances endothelial function, and inhibits both platelet activation and smooth muscle migration.<span class="citation" data-cites="higashi2009">(<a href="references.html#ref-higashi2009" role="doc-biblioref">Higashi et al. 2009</a>)</span></p></li>
<li><p>Hyperglycemia activates protein kinase C and thus accumulation of mitochondrial ROS and prostanoids.<span class="citation" data-cites="geraldes2010">(<a href="references.html#ref-geraldes2010" role="doc-biblioref">Geraldes and King 2010</a>)</span></p></li>
<li><p>Endothelial dysfunction leads to increased endothelin-1 and vasoconstriction.<span class="citation" data-cites="ahlborg2007">(<a href="references.html#ref-ahlborg2007" role="doc-biblioref">Ahlborg et al. 2007</a>)</span></p></li>
</ul></li>
</ul></li>
<li><p><strong><em>Hypertension</em></strong></p>
<ul>
<li><p>The <strong>most common</strong> cardiovascular risk factor worldwide.</p>
<ul>
<li>USPSTF Grade A recommendation for HTN screening confirm readings outside clinical setting or at home before initiating treatment.<span class="citation" data-cites="piper2014">(<a href="references.html#ref-piper2014" role="doc-biblioref">Piper et al. 2014</a>)</span></li>
</ul></li>
<li><p>The Incidence of PAD increases to 2.5-fold in patients with Hypertension. <span class="citation" data-cites="kannelUpdateEpidemiologicFeatures1985">(<a href="references.html#ref-kannelUpdateEpidemiologicFeatures1985" role="doc-biblioref">Kannel and McGee 1985</a>)</span></p></li>
<li><p>Each 20mg increase in BP, results in a 35-63% increase risk in PAD. Recommend keeping BP &lt;140/90 or &lt;130/80 in diabetics or CKD.<span class="citation" data-cites="adler2000 bavry2010 emdin2015 itoga2018">(<a href="references.html#ref-adler2000" role="doc-biblioref">A. I. Adler et al. 2000</a>; <a href="references.html#ref-bavry2010" role="doc-biblioref">Bavry et al. 2010</a>; <a href="references.html#ref-emdin2015" role="doc-biblioref">Emdin et al. 2015</a>; <a href="references.html#ref-itoga2018" role="doc-biblioref">Itoga et al. 2018</a>)</span></p></li>
</ul></li>
<li><p><strong><em>Dyslipidemia</em></strong></p>
<ul>
<li><p>A strong association has long been identified as a risk factor for cardiovascular disease.<span class="citation" data-cites="langlois2018 diehm2004">(<a href="references.html#ref-langlois2018" role="doc-biblioref">Langlois and Nordestgaard 2018</a>; <a href="references.html#ref-diehm2004" role="doc-biblioref">Diehm et al. 2004</a>)</span></p></li>
<li><p>25% cardiovascular event reduction for each 39 mg/dL (1mmol/L) reduction in LDL. <span class="citation" data-cites="heartprotectionstudycollaborativegroupRandomizedTrialEffects2007">(<a href="references.html#ref-heartprotectionstudycollaborativegroupRandomizedTrialEffects2007" role="doc-biblioref">H. P. S. C. Group 2007</a>)</span></p></li>
<li><p>JUPITER Study - Randomized rosuvastatin 20mg to placebo in healthy patients. Found significant decrease in unstable angina, myocardial infarction and stroke. However, patients had a higher incidence of physician-reported diabetes, but no difference in myopathy.<span class="citation" data-cites="ridker2008">(<a href="references.html#ref-ridker2008" role="doc-biblioref">Ridker et al. 2008</a>)</span></p></li>
<li><p>Fish oil is also indicated for secondary prevention among patients with known cardiovascular disease.<span class="citation" data-cites="grenon2012 kris-etherton2002 siscovick2017">(<a href="references.html#ref-grenon2012" role="doc-biblioref">Grenon et al. 2012</a>; <a href="references.html#ref-kris-etherton2002" role="doc-biblioref">Kris-Etherton et al. 2002</a>; <a href="references.html#ref-siscovick2017" role="doc-biblioref">Siscovick et al. 2017</a>)</span></p></li>
</ul></li>
</ol>
<p><strong>Non-Modifiable:</strong></p>
<ol type="1">
<li><p><strong><em>Age</em></strong></p>
<ul>
<li><p>Age is identified as a risk factor for PAD regardless of gender.</p></li>
<li><p>Prevalence of PAD increases with age: 15% &gt; 70 years of age.</p></li>
</ul></li>
<li><p><strong><em>Gender</em></strong></p>
<ul>
<li>The Framingham Study has found that the risk of developing PAD is doubled in men.</li>
</ul></li>
<li><p><strong><em>Race and Ethnicity</em></strong></p>
<ul>
<li><p>The MESA study showed a higher prevalence of PAD (ABPI &lt;0.9) in African Americans compared to Whites. 7.2% versus 3.6%. <span class="citation" data-cites="bildMultiEthnicStudyAtherosclerosis2002">(<a href="references.html#ref-bildMultiEthnicStudyAtherosclerosis2002" role="doc-biblioref">Bild 2002</a>)</span></p></li>
<li><p>Cross Sectional analysis 6653 subjects all with ABPI assessment revealed a prevalence of PAD (&lt;0.9) of 4%. Non-Hispanic Whites: 3.6%, Asian: 2%, African American: 7.2% and Hispanic: 2.4%. (p&lt;0.01) <span class="citation" data-cites="allisonEffectNovelCardiovascular2006">(<a href="references.html#ref-allisonEffectNovelCardiovascular2006" role="doc-biblioref">Allison et al. 2006</a>)</span></p></li>
</ul></li>
</ol>
<p><strong>What are the some of the major population-based trials looking at the natural history of atherosclerotic disease?</strong></p>
<ol type="1">
<li><p><strong><em>The Framingham Heart Study</em></strong>: The original Cohort from the town of Framingham, n=5183 patients, followed over time for over 30 years. There have been multiple subsequent recruited populations since. The majority of information we have about risk factors related to cardiovascular health comes from this study. <span class="citation" data-cites="mahmoodFraminghamHeartStudy2014">(<a href="references.html#ref-mahmoodFraminghamHeartStudy2014" role="doc-biblioref">Mahmood et al. 2014</a>)</span></p></li>
<li><p><strong><em>The Rotterdam Study</em></strong>: 1990, Longitudinal Study, &gt;7000 participants.</p></li>
<li><p><strong><em>CVHS</em></strong>: 1989-1999 Longitudinal Study : n&gt;5000 Multicenter Study.</p></li>
<li><p><strong><em>MESA</em></strong>: Cross Sectional analysis 6653 subjects all with ABPI assessment revealed a prevalence of PAD (&lt;0.9) of 4%. Non-Hispanic Whites: 3.6%, Asian: 2%, African American: 7.2% and Hispanic: 2.4%. (p&lt;0.01) <span class="citation" data-cites="allisonEffectNovelCardiovascular2006">(<a href="references.html#ref-allisonEffectNovelCardiovascular2006" role="doc-biblioref">Allison et al. 2006</a>)</span></p></li>
<li><p><strong><em>The Edinburgh Study</em></strong>: The EAS began as a cross sectional study of 1592 men and women in Edinburgh with the goal of examining the frequency of risk factors for peripheral arterial disease. The subjects were followed over 20 years. <span class="citation" data-cites="fowkesEdinburghArteryStudy1991">(<a href="references.html#ref-fowkesEdinburghArteryStudy1991" role="doc-biblioref">F. G. R. Fowkes et al. 1991</a>)</span></p></li>
</ol>
<p><strong>How does Diabetes confound the clinical picture of PAD?</strong></p>
<ul>
<li><p>Increasing Incidence of Diabetes world-wide.<span class="citation" data-cites="boultonGlobalBurdenDiabetic2005">(<a href="references.html#ref-boultonGlobalBurdenDiabetic2005" role="doc-biblioref">Boulton et al. 2005</a>)</span></p>
<ul>
<li><p>2.8% of the global population affected by diabetes in 2000, estimated to be 4.4% by 2030.</p></li>
<li><p>25% of patients with diabetes develop a diabetic foot ulcer (DFU), at some stage in their lives.</p></li>
<li><p>Diabetic foot ulcers have a very high rate of recurrence with 40% of patients developing a new ulcer within 12 months of healing a previous ulcer. <span class="citation" data-cites="armstrong2017">(<a href="references.html#ref-armstrong2017" role="doc-biblioref">D. G. Armstrong, Boulton, and Bus 2017</a>)</span></p></li>
<li><p>Limb Loss occurs every 20 seconds world-wide to due to Diabetes related PAD or infection.</p></li>
</ul></li>
</ul>
<p><strong>What’s the pathophysiology of Diabetes and PAD</strong> <span class="citation" data-cites="armstrong26PathophysiologyPrinciplesManagement2012">(<a href="references.html#ref-armstrong26PathophysiologyPrinciplesManagement2012" role="doc-biblioref">D. L. Armstrong et al. 2012</a>)</span></p>
<ul>
<li><p>Neuropathy. The loss of the basic nociceptive mechanisms in the foot among diabetics, presents as a loss of protective sensation (LOPS). Neuropathy can be divided into three types:</p>
<ul>
<li><p>Sensory: “stocking-glove” distribution</p></li>
<li><p>Motor: Intrinsic muscle wasting – resulting in deformities</p></li>
<li><p>Autonomic: Sympathetic nervous system pathology</p></li>
</ul></li>
<li><p>Structural deformities and gait disturbances</p></li>
<li><p>Arterial disease of large and small vessels.</p>
<ul>
<li><p>Large Vessel</p></li>
<li><p>Small Vessel</p></li>
<li><p>Both</p></li>
</ul></li>
<li><p>Foot infection<span class="citation" data-cites="bandyk2018 kayssi2019 lepäntalo2011">(<a href="references.html#ref-bandyk2018" role="doc-biblioref">Bandyk 2018</a>; <a href="references.html#ref-kayssi2019" role="doc-biblioref">KAYSSI, ROGERS, and NEVILLE 2019</a>; <a href="references.html#ref-lepäntalo2011" role="doc-biblioref">Lepäntalo et al. 2011</a>)</span></p></li>
</ul>
<p>Given the pathological effect of diabetes upon multiple structures and systems the normal progressive history of diabetes related PAD is somewhat different to smoking related PAD. Clinically due to the combined effect of peripheral neuropathy and microvascular arterial disease, foot ulceration for many patients tends to be the initial presentation. This results in a lack of a ‘safety net’ where presenting with progressive claudication allows for a period of detection, management and and risk factor modification before they develop tissue loss and are at risk of amputation, leading to poor outcomes and greater morbidity and mortality.</p>
<p>Since the publication of WIfI in 2014 a lot has changed in the way we view PAD leading up to last years new Global Vascular Guidelines on CLTI, which as a term has replaced CLI (see <a href="clti.html"><span>Chapter&nbsp;16</span></a>). <span class="citation" data-cites="millsSocietyVascularSurgery2014a conteGlobalVascularGuidelines2019a">(<a href="references.html#ref-millsSocietyVascularSurgery2014a" role="doc-biblioref">Mills et al. 2014</a>; <a href="references.html#ref-conteGlobalVascularGuidelines2019a" role="doc-biblioref">Conte et al. 2019</a>)</span></p>
</section>
<section id="intermittent-claudication" class="level2" data-number="15.2">
<h2 data-number="15.2" class="anchored" data-anchor-id="intermittent-claudication"><span class="header-section-number">15.2</span> Intermittent Claudication</h2>
<p><strong>What is Intermittent Claudication and the classic patient presentation?</strong></p>
<p>The original population studies we mentioned determined the epidemiology and natural history of Intermittent Claudication based on historically validated and widely accepted questionnaires, namely the <strong><em>Rose</em></strong> <span class="citation" data-cites="roseDiagnosisIschaemicHeart1962">(<a href="references.html#ref-roseDiagnosisIschaemicHeart1962" role="doc-biblioref">Rose 1962</a>)</span> (which later was adopted by the WHO) and subsequently the <strong><em>Edinburgh questionnaire</em></strong>. <span class="citation" data-cites="lendEdinburghClaudicationQuestionnaire1992">(<a href="references.html#ref-lendEdinburghClaudicationQuestionnaire1992" role="doc-biblioref">Lend and Fowkes 1992</a>)</span>.</p>
<p>All questionnaires are based on a number of key diagnostic clinical factors that define claudication, they are:</p>
<ul>
<li><p>Onset</p></li>
<li><p>Calf Involvement</p></li>
<li><p>Reproducibility</p></li>
<li><p>Relief with Rest</p></li>
<li><p>Not Occurring at Rest</p></li>
</ul>
<p>The progression of intermittent claudication was historically graded by Fontaine (1954) <span class="citation" data-cites="fontaineSurgicalTreatmentPeripheral1954">(<a href="references.html#ref-fontaineSurgicalTreatmentPeripheral1954" role="doc-biblioref">Fontaine, Kim, and Kieny 1954</a>)</span> followed by the Rutherford Grading System (1986, Revised 1997) <span class="citation" data-cites="rutherfordRecommendedStandardsReports1997">(<a href="references.html#ref-rutherfordRecommendedStandardsReports1997" role="doc-biblioref">Rutherford et al. 1997</a>)</span></p>
<p>Rutherford et al.&nbsp;Ad Hoc Committee on Reporting Standards, SVS/North American Chapter ISCVS:</p>
<table class="table">
<colgroup>
<col style="width: 33%">
<col style="width: 33%">
<col style="width: 33%">
</colgroup>
<thead>
<tr class="header">
<th style="text-align: center;">Grade</th>
<th style="text-align: center;">Category</th>
<th style="text-align: center;">Clinical Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: center;">0</td>
<td style="text-align: center;">0</td>
<td style="text-align: center;">A symptomatic - no hemodynamic significant occlusive disease</td>
</tr>
<tr class="even">
<td style="text-align: center;">I</td>
<td style="text-align: center;">1</td>
<td style="text-align: center;">Mild Claudication</td>
</tr>
<tr class="odd">
<td style="text-align: center;">I</td>
<td style="text-align: center;">2</td>
<td style="text-align: center;">Moderate Claudication</td>
</tr>
<tr class="even">
<td style="text-align: center;">I</td>
<td style="text-align: center;">3</td>
<td style="text-align: center;">Severe Claudication</td>
</tr>
<tr class="odd">
<td style="text-align: center;">II</td>
<td style="text-align: center;">4</td>
<td style="text-align: center;">Ischemic Rest Pain</td>
</tr>
<tr class="even">
<td style="text-align: center;">III</td>
<td style="text-align: center;">5</td>
<td style="text-align: center;">Minor Tissue Loss</td>
</tr>
<tr class="odd">
<td style="text-align: center;">III</td>
<td style="text-align: center;">6</td>
<td style="text-align: center;">Major Tissue Loss</td>
</tr>
</tbody>
</table>
<p><strong>Leriche Syndrome</strong> - Is a clinical triad of: claudication (buttock, thigh, and calf), impotence, and decreased lower limb pulses, which signifies aortoiliac occlusive disease. <span class="citation" data-cites="frederick2010 leriche1948 setacci2012">(<a href="references.html#ref-frederick2010" role="doc-biblioref">Frederick, Newman, and Kohlwes 2010</a>; <a href="references.html#ref-leriche1948" role="doc-biblioref">Leriche and Morel 1948</a>; <a href="references.html#ref-setacci2012" role="doc-biblioref">Setacci et al. 2012</a>)</span></p>
<p><strong>Neurogenic Claudication</strong> - Differentiating neurogenic claudication from vasculogenic claudication can be difficult. Vasculogenic claudication is relieved by cessation of ambulation and mostly affects a unilateral calf. Neurogenic improves with postural changes, more often bilateral and affects the thighs. <span class="citation" data-cites="nadeauReliabilityDifferentiatingNeurogenic2013">(<a href="references.html#ref-nadeauReliabilityDifferentiatingNeurogenic2013" role="doc-biblioref">Nadeau et al. 2013</a>)</span></p>
<p><strong>What is involved in the work up of patients with PAD/Intermittent Claudication?</strong></p>
<section id="history-clinical-examination" class="level3" data-number="15.2.1">
<h3 data-number="15.2.1" class="anchored" data-anchor-id="history-clinical-examination"><span class="header-section-number">15.2.1</span> History / Clinical Examination</h3>
<p><strong><em>SVS Guidelines:</em></strong></p>
<p>“We recommend using ABPI as the first-line non-invasive test to establish a diagnosis of PAD in individuals with symptoms or signs suggestive of disease. When the ABI is borderline or normal (&gt;0.9) and symptoms of claudication are suggestive, we recommend an exercise ABPI.”</p>
<p><em>Grade 1 Level of Evidence A</em></p>
<ul>
<li><p>ABPI</p></li>
<li><p>Exercise ABPI</p></li>
<li><p>Ultrasound</p></li>
</ul>
<p><strong>What is an ABPI and how is it measured?</strong></p>
<p>The AHA released guidelines on how to perform an ABPI in an attempt to standardize the method to allow for more comparable results from studies:</p>
<p>Divide the higher of the PT or DP pressure by the higher of the right or left Brachial SBP <em>(Class 1 Level of Evidence A)</em> <span class="citation" data-cites="aboyansMeasurementInterpretationAnkleBrachial2012">(<a href="references.html#ref-aboyansMeasurementInterpretationAnkleBrachial2012" role="doc-biblioref">Aboyans et al. 2012</a>)</span></p>
<p>Sensitivity and Specificity both &gt;95% (when ABPI cut off &lt;/=0.9 – in detecting &gt;/= 50% stenosis) <span class="citation" data-cites="yaoAnkleSystolicPressure2005 ourielCriticalEvaluationStress1982">(<a href="references.html#ref-yaoAnkleSystolicPressure2005" role="doc-biblioref">Yao, Hobbs, and Irivne 2005</a>; <a href="references.html#ref-ourielCriticalEvaluationStress1982" role="doc-biblioref">Ouriel et al. 1982</a>)</span></p>
<table class="table">
<caption>Interpretation of ABPIs.</caption>
<thead>
<tr class="header">
<th style="text-align: center;"><strong>ABPI</strong></th>
<th style="text-align: center;">Interpretation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: center;">&gt;1.4</td>
<td style="text-align: center;">Non-compressible</td>
</tr>
<tr class="even">
<td style="text-align: center;">&gt;0.9-1.39</td>
<td style="text-align: center;">Normal</td>
</tr>
<tr class="odd">
<td style="text-align: center;">0.5-0.9</td>
<td style="text-align: center;">Mild to Mod PAD</td>
</tr>
<tr class="even">
<td style="text-align: center;">0.0-0.5</td>
<td style="text-align: center;">Severe PAD</td>
</tr>
</tbody>
</table>
<p><strong>What are Exercise ABPI studies?</strong></p>
<p>Constant Load Testing – (unlike the Graded Test – Bruce Protocol).</p>
<p>The physiological changes in ABPI related to exercise are due to the fact that exercise increases SBP and decreases SVR and, therefore, will affect flow through a stenosis making it more physiologically relevant during exercise. <span class="citation" data-cites="nicolaiReliabilityTreadmillTesting2009 alqahtaniPredictorsChangeAnkleBrachial2018">(<a href="references.html#ref-nicolaiReliabilityTreadmillTesting2009" role="doc-biblioref">Nicolaï et al. 2009</a>; <a href="references.html#ref-alqahtaniPredictorsChangeAnkleBrachial2018" role="doc-biblioref">Alqahtani et al. 2018</a>)</span></p>
<p>Walking distance has been shown to correlate with level and severity of POAD. <span class="citation" data-cites="strandnessHemodynamicsSurgeons1975a">(<a href="references.html#ref-strandnessHemodynamicsSurgeons1975a" role="doc-biblioref">Strandness and Sumner 1975</a>)</span></p>
<p>Furthermore patients with single level iliac disease may present with buttock/thigh claudication with preserved pulses. Exercise treadmill ABPI particularly useful in determining the severity of disease in these patients. <span class="citation" data-cites="aboyansGeneralPrognosisPatients2010">(<a href="references.html#ref-aboyansGeneralPrognosisPatients2010" role="doc-biblioref">Aboyans et al. 2010</a>)</span></p>
<p>For more on exercise testing see <a href="vascular-lab.html#sec-lab-lower-extremity"><span>Section&nbsp;20.5</span></a></p>
<p><strong>What is the ultrasound duplex criteria for defining PAD?</strong></p>
<table class="table">
<colgroup>
<col style="width: 25%">
<col style="width: 25%">
<col style="width: 25%">
<col style="width: 25%">
</colgroup>
<thead>
<tr class="header">
<th style="text-align: center;">Stenosis Category</th>
<th style="text-align: center;">Peak Systolic Velocity</th>
<th style="text-align: center;">Velocity Ratio</th>
<th style="text-align: center;">Distal Artery Spectral Waveform</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: center;">Normal</td>
<td style="text-align: center;">&lt;150</td>
<td style="text-align: center;">&lt;1.5</td>
<td style="text-align: center;">Triphasic, Normal PSV</td>
</tr>
<tr class="even">
<td style="text-align: center;">30-49%</td>
<td style="text-align: center;">150-200</td>
<td style="text-align: center;">1.5-2</td>
<td style="text-align: center;">Triphasic, Normal PSV</td>
</tr>
<tr class="odd">
<td style="text-align: center;">50-75%</td>
<td style="text-align: center;">200-400</td>
<td style="text-align: center;">2-4</td>
<td style="text-align: center;">Monophasic, reduced PSV</td>
</tr>
<tr class="even">
<td style="text-align: center;">&gt;75%</td>
<td style="text-align: center;">&gt;400</td>
<td style="text-align: center;">&gt;4</td>
<td style="text-align: center;">Damped, monophasic, reduced PSV</td>
</tr>
<tr class="odd">
<td style="text-align: center;">Occlusion</td>
<td style="text-align: center;">No Flow – B -mode, Terminal Thump</td>
<td style="text-align: center;">NA</td>
<td style="text-align: center;">NA</td>
</tr>
</tbody>
</table>
<p>Adapted from Stone and Hass. Vascular Laboratory: Arterial Duplex Scanning. Rutherford’s Vascular Surgery and Endovascular Therapy. 2019.<span class="citation" data-cites="stone21VascularLaboratory2019">(<a href="references.html#ref-stone21VascularLaboratory2019" role="doc-biblioref">Stone and Hass 2019</a>)</span></p>
<p><strong>What Guidelines are there pertaining to PAD Management.</strong></p>
<p><strong><em>SVS Guidelines (2015)</em></strong></p>
<ul>
<li>The SVS published the SVS practice guidelines for atherosclerotic occlusive disease of the lower extremities:<strong>Management of asymptomatic disease and claudication</strong>. <em>Conte and Pomposelli et al.&nbsp;JVS 2015</em> <span class="citation" data-cites="conteSocietyVascularSurgery2015">(<a href="references.html#ref-conteSocietyVascularSurgery2015" role="doc-biblioref">Conte, Pomposelli, Clair, Geraghty, McKinsey, Mills, Moneta, Murad, Powell, Reed, Schanzer, et al. 2015</a>)</span></li>
</ul>
<p>Other Guidelines:</p>
<ul>
<li><p>TASC 1 -2</p></li>
<li><p>European Guidelines (2017)</p></li>
<li><p>AHA Guidelines (last update 2016)</p></li>
</ul>
</section>
<section id="management" class="level3" data-number="15.2.2">
<h3 data-number="15.2.2" class="anchored" data-anchor-id="management"><span class="header-section-number">15.2.2</span> Management</h3>
<section id="sec-pad-medical-management" class="level4" data-number="15.2.2.1">
<h4 data-number="15.2.2.1" class="anchored" data-anchor-id="sec-pad-medical-management"><span class="header-section-number">15.2.2.1</span> Medical Management</h4>
<p><strong>What is the initial management of Asymptomatic Patients with PAD?</strong></p>
<ol type="1">
<li>Smoking Cessation – Multidisciplinary comprehensive smoking cessation interventions – repeatedly until tobacco use has stopped (Grade A – 1)</li>
<li>Intervention is not only not recommended, but invasive treatment is recommended against, in the absence of symptoms (Grade A -1)</li>
</ol>
<p><strong>How can we medically manage asymptomatic PAD based on the SVS Guidelines?</strong></p>
<ul>
<li><p><strong><em>Anti-Platelet Therapy</em></strong></p>
<ul>
<li>The Aspirin for Asymptomatic Atherosclerosis Trial – n=3350, aspirin versus placebo. 8 years follow up no difference in events <span class="citation" data-cites="fowkesAspirinPreventionCardiovascular2010">(<a href="references.html#ref-fowkesAspirinPreventionCardiovascular2010" role="doc-biblioref">F. Gerald R. Fowkes 2010</a>)</span> – therefore benefit unknown</li>
<li>Literature reviews find benefits in secondary prevention with antiplatelet monotherapy (aspirin or clopidogrel) in symptomatic PAD.<span class="citation" data-cites="banerjee2015">(<a href="references.html#ref-banerjee2015" role="doc-biblioref">Banerjee et al. 2015</a>)</span> Some initial studies did demonstrate benefit from vorapaxar as well.<span class="citation" data-cites="rooke2013">(<a href="references.html#ref-rooke2013" role="doc-biblioref">Rooke et al. 2013</a>)</span></li>
</ul></li>
<li><p><strong><em>Statin Therapy</em></strong></p>
<ul>
<li><p>The Heart Protection Study <span class="citation" data-cites="heartprotectionstudycollaborativegroupRandomizedTrialEffects2007">(<a href="references.html#ref-heartprotectionstudycollaborativegroupRandomizedTrialEffects2007" role="doc-biblioref">H. P. S. C. Group 2007</a>)</span> - this study looked at statins in patients with PAD but not completely asymptomatic, they had other risk factors such as diabetes, IHD, cerebrovascular disease, or hypertension. Without these risk factors the benefit of Statin therapy remains unclear.</p></li>
<li><p>However, the AHA from the Framingham Study does recommend using statins if 10-year risk based on risk calculators &gt;7.5% (which would be positive if PAD present).</p></li>
<li><p>Statins are particularly useful for risk reduction of cardiovascular events in diabetics.<span class="citation" data-cites="cholesteroltreatmenttrialists2008 colhoun2004 stamler1993">(<a href="references.html#ref-cholesteroltreatmenttrialists2008" role="doc-biblioref">Collaborators et al. 2008</a>; <a href="references.html#ref-colhoun2004" role="doc-biblioref">Colhoun et al. 2004</a>; <a href="references.html#ref-stamler1993" role="doc-biblioref">Stamler et al. 1993</a>)</span></p></li>
<li><p>Statin-associated muscle symptoms (SAMS) is the most common side effect and occurrence has been reported as high as 30% in some cohorts.<span class="citation" data-cites="keen2014">(<a href="references.html#ref-keen2014" role="doc-biblioref">Keen et al. 2014</a>)</span> Other side effects are rare (1.5-5% of patients) and include DM2 new onset, neurocognitive effects, hepatotoxicity, renal toxicity and pancreatitis.<span class="citation" data-cites="bitzur2013 saxon2016 ward2019">(<a href="references.html#ref-bitzur2013" role="doc-biblioref">Bitzur et al. 2013</a>; <a href="references.html#ref-saxon2016" role="doc-biblioref">Saxon and Eckel 2016</a>; <a href="references.html#ref-ward2019" role="doc-biblioref">Ward, Watts, and Eckel 2019</a>)</span></p></li>
</ul></li>
<li><p><strong><em>Exercise and Limb Function</em></strong></p>
<ul>
<li>No clear evidence that physical therapy improves the patient outcomes or quality of life.</li>
</ul></li>
<li><p><strong><em>Surveillance</em></strong></p>
<ul>
<li>No benefit from US surveillance, unclear benefit of ABPI surveillance.</li>
<li>Patients are at higher risk of depression (almost 20%), therefore PHQ-9 and -2 are good screening tools.<span class="citation" data-cites="jha2019 mcdermott2016 ramirez2018">(<a href="references.html#ref-jha2019" role="doc-biblioref">Jha et al. 2019</a>; <a href="references.html#ref-mcdermott2016" role="doc-biblioref">McDermott et al. 2016</a>; <a href="references.html#ref-ramirez2018" role="doc-biblioref">Ramirez, Drudi, and Grenon 2018</a>)</span></li>
</ul></li>
</ul>
<p><strong>How can we medically manage Intermittent Claudication based on the SVS Guidelines?</strong></p>
<ul>
<li><p><strong>Smoking Cessation:</strong> Multidisciplinary comprehensive smoking cessation interventions – repeatedly until tobacco use has stopped <em>(Grade A – 1)</em> First line therapy is behavioral therapy + varenicline/bupropion or nicotine replacement therapy (NRT) per EAGLES trial.<span class="citation" data-cites="anthenelli2016 vogeler2016">(<a href="references.html#ref-anthenelli2016" role="doc-biblioref">Anthenelli et al. 2016</a>; <a href="references.html#ref-vogeler2016" role="doc-biblioref">Vogeler, McClain, and Evoy 2016</a>)</span></p>
<ul>
<li><p>Preloading with varenicline (4 weeks) or bupropion (5-7d) prior to quitting has demonstrated higher abstinence at 12w.<span class="citation" data-cites="ratchford2011">(<a href="references.html#ref-ratchford2011" role="doc-biblioref">Ratchford and Black 2011</a>)</span></p>
<ul>
<li><p>Varenicline is a partial nicotine receptor agonist.<span class="citation" data-cites="cahill2016">(<a href="references.html#ref-cahill2016" role="doc-biblioref">Cahill et al. 2016</a>)</span></p></li>
<li><p>Bupropion is a selective dopamine and norepinephrine uptake inhibitor.<span class="citation" data-cites="hughes2014">(<a href="references.html#ref-hughes2014" role="doc-biblioref">Hughes et al. 2014</a>)</span></p></li>
</ul></li>
<li><p>NRT is preferred if rapid onset of action is needed.<span class="citation" data-cites="thomsen2014">(<a href="references.html#ref-thomsen2014" role="doc-biblioref">Thomsen, Villebro, and Møller 2014</a>)</span> However, contraindicated in setting of recent MI, severe angina, or life threatening arrhythmias.</p></li>
</ul></li>
<li><p><strong>Dyslipidaemia:</strong> Statin Therapy Recommended – most recent evidence on lipid therapy has suggested focusing on reducing 10-year cardiovascular event risk rather than specifically reducing lipid levels. <em>(Grade 1-A)</em></p></li>
<li><p><strong>Anti-Platelet Therapy:</strong> Aspirin therapy (75-325mg daily) is recommended to reduce cardiovascular events in patients with PAD <em>(Grade 1-Level A)</em> <span class="citation" data-cites="collaborationCollaborativeMetaanalysisRandomised2002 antithrombotictrialists2009">(<a href="references.html#ref-collaborationCollaborativeMetaanalysisRandomised2002" role="doc-biblioref">Antithrombotic Trialists’Collaboration 2002</a>; <a href="references.html#ref-antithrombotictrialists2009" role="doc-biblioref">Antithrombotic Trialists’(ATT) Collaboration et al. 2009</a>)</span></p>
<ul>
<li>There is evidence that Clopidogrel 75mg compared to Aspirin is better in event reduction. (CAPRIE)<span class="citation" data-cites="capriesteeringcommitteeRandomisedBlindedTrial1996">(<a href="references.html#ref-capriesteeringcommitteeRandomisedBlindedTrial1996" role="doc-biblioref">Committee 1996</a>)</span>– replacing Aspirin with Clopidogrel <em>(Grade 1-Level B)</em></li>
<li>Recent evidence from the COMPASS trial has suggested that the addition of low dose rivaroxaban (2.5mg BID) to aspirin (100mg daily) has lower MALE, composite endpoint of cardiovascular death, stroke and MI. Subgroup analysis suggested clopidogrel may be better with reduced risk of GI bleed and MACE.<span class="citation" data-cites="anand2018 eikelboom2017">(<a href="references.html#ref-anand2018" role="doc-biblioref">Anand et al. 2018</a>; <a href="references.html#ref-eikelboom2017" role="doc-biblioref">Eikelboom et al. 2017</a>)</span></li>
</ul></li>
<li><p><strong>Diabetes Mellitus:</strong> – Optimization of HbA1C &lt; 7% <em>(Grade 1-Level B)</em><span class="citation" data-cites="lajoie2019">(<a href="references.html#ref-lajoie2019" role="doc-biblioref">Lajoie 2019</a>)</span></p></li>
<li><p><strong>Hypertension</strong> – Indicated B-Blockers for hypertension. <em>(Grade 1-Level B)</em> (there’s no evidence that Beta Blockers worsens IC)</p>
<ul>
<li><p>Initiation of beta-blockers in the immediate preoperative period is associated with worse outcomes.<span class="citation" data-cites="blessberger2018 poisestudygroup2008">(<a href="references.html#ref-blessberger2018" role="doc-biblioref">Blessberger et al. 2018</a>; <a href="references.html#ref-poisestudygroup2008" role="doc-biblioref">P. S. Group et al. 2008</a>)</span></p></li>
<li><p>ACE Inhibitors are first line in patients with heart failure, diabetes or kidney disease but should be avoided in patients with renal artery stenosis (RAS).<span class="citation" data-cites="barrons2016">(<a href="references.html#ref-barrons2016" role="doc-biblioref">Barrons and Woods 2016</a>)</span></p></li>
</ul></li>
<li><p><strong>Homocysteine</strong> – Recommendation against Folic Acid and Vit B12<em>(Grade 2 – C)</em></p>
<ul>
<li>Higher homocysteine levels are associated with PAD and risk of venous and arterial thrombosis.<span class="citation" data-cites="dangelo1997 khandanpour2009 liebman2019">(<a href="references.html#ref-dangelo1997" role="doc-biblioref">D’Angelo and Selhub 1997</a>; <a href="references.html#ref-khandanpour2009" role="doc-biblioref">Khandanpour et al. 2009</a>; <a href="references.html#ref-liebman2019" role="doc-biblioref">Liebman 2019</a>)</span></li>
</ul></li>
</ul>
<p><strong>To improve Limb Function in patients with IC:</strong></p>
<ul>
<li><p><strong>Cilostozol</strong> use – IC without CHF – 3-month Trial (Grade 2 - A)</p>
<ul>
<li><p>If unable to tolerate Cilostozol – Pentoxifylline (400mg TDS) <em>(Grade 2 – B)</em></p></li>
<li><p>Based on Meta-analysis 26 trials <span class="citation" data-cites="stevensSystematicReviewEfficacy2012">(<a href="references.html#ref-stevensSystematicReviewEfficacy2012" role="doc-biblioref">Stevens et al. 2012</a>)</span></p></li>
</ul></li>
<li><p><strong>Supervised Exercise Therapy</strong></p>
<ul>
<li><p>First Line Therapy recommended SEP: minimum three times / week (30-60 min/session) for at least 12 weeks (<em>Grade 1 Level A</em>)</p></li>
<li><p>More durable functional improvements than angioplasty alone, however no current data demonstrating impact on need for revascularization or amputation rate.<span class="citation" data-cites="fakhry2013 fakhry2015 murphy2012 murphy2015">(<a href="references.html#ref-fakhry2013" role="doc-biblioref">F. Fakhry et al. 2013</a>; <a href="references.html#ref-fakhry2015" role="doc-biblioref">Farzin Fakhry et al. 2015</a>; <a href="references.html#ref-murphy2012" role="doc-biblioref">Murphy et al. 2012</a>, <a href="references.html#ref-murphy2015" role="doc-biblioref">2015</a>)</span></p></li>
<li><p>Meta-analysis of 32 RCTs: Placebo versus exercise: Walking Time, Walking Ability, Pain Free Walking and maximum walking distance improves. BUT no difference in ABPI, Mortality or amputation. <span class="citation" data-cites="laneExerciseIntermittentClaudication2017">(<a href="references.html#ref-laneExerciseIntermittentClaudication2017" role="doc-biblioref">Lane et al. 2017</a>)</span></p></li>
<li><p>Meta-analysis of 14 RCTs: SEP better than Non-Supervised Programs. <span class="citation" data-cites="hagemanSupervisedExerciseTherapy2018">(<a href="references.html#ref-hagemanSupervisedExerciseTherapy2018" role="doc-biblioref">Hageman et al. 2018</a>)</span></p></li>
</ul></li>
</ul>
</section>
<section id="open-and-endovascular-management" class="level4" data-number="15.2.2.2">
<h4 data-number="15.2.2.2" class="anchored" data-anchor-id="open-and-endovascular-management"><span class="header-section-number">15.2.2.2</span> Open and Endovascular Management</h4>
<p><strong>What is the surgical management for patients with Intermittent Claudication?</strong></p>
<ul>
<li><p>With appropriate medical management and risk modification, 25% of patients will improve, 50% will remain stable and 25% will progress and requiring intervention. <span class="citation" data-cites="conte2015 norgren2007">(<a href="references.html#ref-conte2015" role="doc-biblioref">Conte, Pomposelli, Clair, Geraghty, McKinsey, Mills, Moneta, Murad, Powell, Reed, and al. 2015</a>; <a href="references.html#ref-norgren2007" role="doc-biblioref">Norgren et al. 2007</a>)</span></p></li>
<li><p><strong>Patient Selection for Intervention:</strong></p>
<ul>
<li><p>20-30% of patients with IC who adhere to risk factor modification will have progressive symptoms that will eventually be treated with intervention.</p></li>
<li><p>Patient selection should be based on QoL and functional impairment in an active person (loss of ability to perform occupation or that limits basic activities of daily living) rather than hemodynamic (ABPI or US) or anatomical disease progression/severity.</p></li>
</ul></li>
<li><p><strong>Always remember multifactorial causes of immobility – particularly in the elderly.</strong></p>
<ul>
<li>SVS recommends that invasive therapy for IC have a &gt;50% likelihood of sustained clinical improvement for at least 2 years.</li>
</ul></li>
<li><p><strong>Anatomical Selection:</strong></p>
<ul>
<li><p><strong><em>Aortoiliac Disease:</em></strong></p>
<ul>
<li><p>Previous TASC Classification has attempted to categorize anatomy of disease and subsequent recommendation of Endovascular versus open surgery. But as the authors of the SVS guidelines highlight, “improvements in technology and endovascular techniques have resulted in EVT replacing open surgical bypass as a primary treatment for both focal and advanced AIOD in many cases.”</p></li>
<li><p><strong>The majority of evidence is non randomized and meta analyses of non-randomized series.</strong></p></li>
<li><p>Endovascular procedures over open surgery for focal AIOD causing IC. <em>(Grade 1 Evidence B)</em></p></li>
<li><p>Endovascular interventions as first line for CIA or EIZ occlusive disease-causing IC. <em>(Grade 1 Level B)</em></p></li>
<li><p>Hybrid recommended for Iliac disease involving CFA. <em>(Grade 1 Level B)</em></p></li>
<li><p>Direct Surgical reconstruction (bypass, endarterectomy) in patients with reasonable surgical risk and diffuse AIOD not amenable to endovascular approach, after one or more failed attempts at EVT, or combined occlusive and aneurysmal disease. <em>(Grade 1 Evidence B)</em></p></li>
</ul></li>
<li><p><strong><em>Infrainguinal Disease:</em></strong></p>
<ul>
<li><p>Reviewing historical data comparing all EVT compared with surgical bypass EVTs are less durable, especially when there’s diffuse or long segments of occlusion/multilevel infrainguinal disease.</p></li>
<li><p><strong>Most recommendations are based on low level evidence when comparing EVT versus Open Surgery</strong></p></li>
<li><p>Focal + Not involving SFA origin = EVT <em>(Grade 1 Level C)</em></p></li>
<li><p>SFA 5-15cm, self-expanding stent (with or without paclitaxel) <em>(Grade 1 Level B)</em> – NB: (This was in 2015 pre Katsanos Paper<span class="citation" data-cites="katsanos2018">(<a href="references.html#ref-katsanos2018" role="doc-biblioref">Katsanos et al. 2018</a>)</span>)</p>
<ul>
<li>After SFA stenting, SVS and ACC recommend at least 30d dual anti-platelet, then single anti-platelet or anti-platelet and rivaroxaban.<span class="citation" data-cites="hussain2018 societyforvascularsurgerylowerextremityguidelineswritinggroup2015 strobl2013 tepe2012">(<a href="references.html#ref-hussain2018" role="doc-biblioref">Hussain et al. 2018</a>; <a href="references.html#ref-societyforvascularsurgerylowerextremityguidelineswritinggroup2015" role="doc-biblioref">Vascular Surgery Lower Extremity Guidelines Writing Group et al. 2015</a>; <a href="references.html#ref-strobl2013" role="doc-biblioref">Strobl et al. 2013</a>; <a href="references.html#ref-tepe2012" role="doc-biblioref">Tepe et al. 2012</a>)</span></li>
</ul></li>
<li><p>Recommend against infrapopliteal treatment for IC <em>(Grade 1 Level C)</em></p></li>
<li><p>Initial Surgical Bypass <em>(with vein: Grade 1 Level A)</em>: If</p>
<ul>
<li><p>Diffuse FP Disease</p></li>
<li><p>Small Caliber &lt;5mm</p></li>
<li><p>Extensive Calcification in SFA</p></li>
<li><p>Average or Low Operative Risk <em>(Grade 1 Level B)</em></p></li>
</ul></li>
</ul></li>
</ul></li>
</ul>


<div id="refs" class="references csl-bib-body hanging-indent" role="doc-bibliography" style="display: none">
<div id="ref-aboyansMeasurementInterpretationAnkleBrachial2012" class="csl-entry" role="doc-biblioentry">
Aboyans, Victor, Michael H. Criqui, Pierre Abraham, Matthew A. Allison, Mark A. Creager, Curt Diehm, F. Gerry R. Fowkes, et al. 2012. <span>“Measurement and <span>Interpretation</span> of the <span>Ankle-Brachial Index</span>: <span>A Scientific Statement From</span> the <span>American Heart Association</span>.”</span> <em>Circulation</em> 126 (24): 2890–2909. <a href="https://doi.org/10.1161/CIR.0b013e318276fbcb">https://doi.org/10.1161/CIR.0b013e318276fbcb</a>.
</div>
<div id="ref-aboyansGeneralPrognosisPatients2010" class="csl-entry" role="doc-biblioentry">
Aboyans, Victor, Ileana Desormais, Philippe Lacroix, Johanna Salazar, Michael H. Criqui, and Marc Laskar. 2010. <span>“The <span>General Prognosis</span> of <span>Patients With Peripheral Arterial Disease Differs According</span> to the <span>Disease Localization</span>.”</span> <em>Journal of the American College of Cardiology</em> 55 (9): 898–903. <a href="https://doi.org/10.1016/j.jacc.2009.09.055">https://doi.org/10.1016/j.jacc.2009.09.055</a>.
</div>
<div id="ref-aboyans2017ESCGuidelines2018" class="csl-entry" role="doc-biblioentry">
Aboyans, Victor, Jean-Baptiste Ricco, Marie-Louise E L Bartelink, Martin Björck, Marianne Brodmann, Tina Cohnert, Jean-Philippe Collet, et al. 2018. <span>“2017 <span>ESC Guidelines</span> on the <span>Diagnosis</span> and <span>Treatment</span> of <span>Peripheral Arterial Diseases</span>, in Collaboration with the <span>European Society</span> for <span>Vascular Surgery</span> (<span>ESVS</span>).”</span> <em>European Heart Journal</em> 39 (9): 763–816. <a href="https://doi.org/10.1093/eurheartj/ehx095">https://doi.org/10.1093/eurheartj/ehx095</a>.
</div>
<div id="ref-adler2000" class="csl-entry" role="doc-biblioentry">
Adler, A. I., I. M. Stratton, H. A. Neil, J. S. Yudkin, D. R. Matthews, C. A. Cull, A. D. Wright, R. C. Turner, and R. R. Holman. 2000. <span>“Association of Systolic Blood Pressure with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 36): Prospective Observational Study.”</span> <em>BMJ (Clinical Research Ed.)</em> 321 (7258): 412–19. <a href="https://doi.org/10.1136/bmj.321.7258.412">https://doi.org/10.1136/bmj.321.7258.412</a>.
</div>
<div id="ref-adlerUKPDS59Hyperglycemia2002" class="csl-entry" role="doc-biblioentry">
Adler, Amanda I., Richard J. Stevens, Andrew Neil, Irene M. Stratton, Andrew J. M. Boulton, Rury R. Holman, and for the U.K. Prospective Diabetes Study Group. 2002. <span>“<span>UKPDS</span> 59: <span>Hyperglycemia</span> and <span>Other Potentially Modifiable Risk Factors</span> for <span>Peripheral Vascular Disease</span> in <span>Type</span> 2 <span>Diabetes</span>.”</span> <em>Diabetes Care</em> 25 (5): 894–99. <a href="https://doi.org/10.2337/diacare.25.5.894">https://doi.org/10.2337/diacare.25.5.894</a>.
</div>
<div id="ref-ahlborg2007" class="csl-entry" role="doc-biblioentry">
Ahlborg, Gunvor, Alexey Shemyakin, Felix Böhm, Adrian Gonon, and John Pernow. 2007. <span>“Dual Endothelin Receptor Blockade Acutely Improves Insulin Sensitivity in Obese Patients with Insulin Resistance and Coronary Artery Disease.”</span> <em>Diabetes Care</em> 30 (3): 591–96. <a href="https://doi.org/10.2337/dc06-1978">https://doi.org/10.2337/dc06-1978</a>.
</div>
<div id="ref-allisonEffectNovelCardiovascular2006" class="csl-entry" role="doc-biblioentry">
Allison, Matthew A., Michael H. Criqui, Robyn L. McClelland, JoAnn M. Scott, Mary M. McDermott, Kiang Liu, Aaron R. Folsom, et al. 2006. <span>“The <span>Effect</span> of <span>Novel Cardiovascular Risk Factors</span> on the <span>Ethnic-Specific Odds</span> for <span>Peripheral Arterial Disease</span> in the <span>Multi-Ethnic Study</span> of <span>Atherosclerosis</span> (<span>MESA</span>).”</span> <em>Journal of the American College of Cardiology</em> 48 (6): 1190–97. <a href="https://doi.org/10.1016/j.jacc.2006.05.049">https://doi.org/10.1016/j.jacc.2006.05.049</a>.
</div>
<div id="ref-alqahtaniPredictorsChangeAnkleBrachial2018" class="csl-entry" role="doc-biblioentry">
Alqahtani, Khalid M., Munveer Bhangoo, Florin Vaida, Julie O. Denenberg, Matthew A. Allison, and Michael H. Criqui. 2018. <span>“Predictors of <span>Change</span> in the <span>Ankle-Brachial Index</span> with <span>Exercise</span>.”</span> <em>European Journal of Vascular and Endovascular Surgery : The Official Journal of the European Society for Vascular Surgery</em> 55 (3): 399–404. <a href="https://doi.org/10.1016/j.ejvs.2017.12.004">https://doi.org/10.1016/j.ejvs.2017.12.004</a>.
</div>
<div id="ref-anand2018" class="csl-entry" role="doc-biblioentry">
Anand, Sonia S., Francois Caron, John W. Eikelboom, Jackie Bosch, Leanne Dyal, Victor Aboyans, Maria Teresa Abola, et al. 2018. <span>“Major Adverse Limb Events and Mortality in Patients with Peripheral Artery Disease: The COMPASS Trial.”</span> <em>Journal of the American College of Cardiology</em> 71 (20): 2306–15. <a href="https://doi.org/10.1016/j.jacc.2018.03.008">https://doi.org/10.1016/j.jacc.2018.03.008</a>.
</div>
<div id="ref-anthenelli2016" class="csl-entry" role="doc-biblioentry">
Anthenelli, Robert M., Neal L. Benowitz, Robert West, Lisa St Aubin, Thomas McRae, David Lawrence, John Ascher, Cristina Russ, Alok Krishen, and A. Eden Evins. 2016. <span>“Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers with and Without Psychiatric Disorders (EAGLES): A Double-Blind, Randomised, Placebo-Controlled Clinical Trial.”</span> <em>Lancet (London, England)</em> 387 (10037): 2507–20. <a href="https://doi.org/10.1016/S0140-6736(16)30272-0">https://doi.org/10.1016/S0140-6736(16)30272-0</a>.
</div>
<div id="ref-armstrong2017" class="csl-entry" role="doc-biblioentry">
Armstrong, David G., Andrew J. M. Boulton, and Sicco A. Bus. 2017. <span>“Diabetic Foot Ulcers and Their Recurrence.”</span> <em>The New England Journal of Medicine</em> 376 (24): 2367–75. <a href="https://doi.org/10.1056/NEJMra1615439">https://doi.org/10.1056/NEJMra1615439</a>.
</div>
<div id="ref-armstrong26PathophysiologyPrinciplesManagement2012" class="csl-entry" role="doc-biblioentry">
Armstrong, David L, Timothy K Fisher, Brian Lepow, Matthew L White, and Joseph L Mills. 2012. <span>“<span>26Pathophysiology</span> and <span>Principles</span> of <span>Management</span> of the <span>Diabetic Foot</span>.”</span> In <em>Mechanisms of <span>Vascular Disease</span>: <span>A Reference Book</span> for <span>Vascular Specialists</span></em>. <span>Adelaide</span>: <span>University of Adelaide Press</span>. <a href="https://doi.org/10.1017/UPO9781922064004">https://doi.org/10.1017/UPO9781922064004</a>.
</div>
<div id="ref-bandyk2018" class="csl-entry" role="doc-biblioentry">
Bandyk, Dennis F. 2018. <span>“The Diabetic Foot: Pathophysiology, Evaluation, and Treatment.”</span> <em>Seminars in Vascular Surgery</em> 31 (2-4): 43–48. <a href="https://doi.org/10.1053/j.semvascsurg.2019.02.001">https://doi.org/10.1053/j.semvascsurg.2019.02.001</a>.
</div>
<div id="ref-banerjee2015" class="csl-entry" role="doc-biblioentry">
Banerjee, Subhash, Karan Sarode, Ariel Vinas, Avantika Banerjee, Atif Mohammad, and Emmanouil S. Brilakis. 2015. <span>“The Role of Antiplatelet Therapy in Patients with Peripheral Artery Disease and Lower Extremity Peripheral Artery Revascularization.”</span> <em>Current Opinion in Cardiology</em> 30 (5): 525–35. <a href="https://doi.org/10.1097/HCO.0000000000000208">https://doi.org/10.1097/HCO.0000000000000208</a>.
</div>
<div id="ref-barrons2016" class="csl-entry" role="doc-biblioentry">
Barrons, Robert W., and J. Andrew Woods. 2016. <span>“The Roles of ACE Inhibitors in Lower Extremity Peripheral Artery Disease.”</span> <em>American Journal of Therapeutics</em> 23 (1): e7–15. <a href="https://doi.org/10.1097/MJT.0000000000000011">https://doi.org/10.1097/MJT.0000000000000011</a>.
</div>
<div id="ref-bavry2010" class="csl-entry" role="doc-biblioentry">
Bavry, Anthony A., R. David Anderson, Yan Gong, Scott J. Denardo, Rhonda M. Cooper-Dehoff, Eileen M. Handberg, and Carl J. Pepine. 2010. <span>“Outcomes Among Hypertensive Patients with Concomitant Peripheral and Coronary Artery Disease: Findings from the INternational VErapamil-SR/Trandolapril STudy.”</span> <em>Hypertension (Dallas, Tex.: 1979)</em> 55 (1): 48–53. <a href="https://doi.org/10.1161/HYPERTENSIONAHA.109.142240">https://doi.org/10.1161/HYPERTENSIONAHA.109.142240</a>.
</div>
<div id="ref-bildMultiEthnicStudyAtherosclerosis2002" class="csl-entry" role="doc-biblioentry">
Bild, D. E. 2002. <span>“Multi-<span>Ethnic Study</span> of <span>Atherosclerosis</span>: <span>Objectives</span> and <span>Design</span>.”</span> <em>American Journal of Epidemiology</em> 156 (9): 871–81. <a href="https://doi.org/10.1093/aje/kwf113">https://doi.org/10.1093/aje/kwf113</a>.
</div>
<div id="ref-bitzur2013" class="csl-entry" role="doc-biblioentry">
Bitzur, Rafael, Hofit Cohen, Yehuda Kamari, and Dror Harats. 2013. <span>“Intolerance to Statins: Mechanisms and Management.”</span> <em>Diabetes Care</em> 36 Suppl 2 (August): S325–330. <a href="https://doi.org/10.2337/dcS13-2038">https://doi.org/10.2337/dcS13-2038</a>.
</div>
<div id="ref-blessberger2018" class="csl-entry" role="doc-biblioentry">
Blessberger, Hermann, Juergen Kammler, Hans Domanovits, Oliver Schlager, Brigitte Wildner, Danyel Azar, Martin Schillinger, Franz Wiesbauer, and Clemens Steinwender. 2018. <span>“Perioperative Beta-Blockers for Preventing Surgery-Related Mortality and Morbidity.”</span> <em>The Cochrane Database of Systematic Reviews</em> 3 (March): CD004476. <a href="https://doi.org/10.1002/14651858.CD004476.pub3">https://doi.org/10.1002/14651858.CD004476.pub3</a>.
</div>
<div id="ref-boultonGlobalBurdenDiabetic2005" class="csl-entry" role="doc-biblioentry">
Boulton, Andrew JM, Loretta Vileikyte, Gunnel Ragnarson-Tennvall, and Jan Apelqvist. 2005. <span>“The Global Burden of Diabetic Foot Disease.”</span> <em>The Lancet</em> 366 (9498): 1719–24. <a href="https://doi.org/10.1016/S0140-6736(05)67698-2">https://doi.org/10.1016/S0140-6736(05)67698-2</a>.
</div>
<div id="ref-cahill2016" class="csl-entry" role="doc-biblioentry">
Cahill, Kate, Nicola Lindson-Hawley, Kyla H. Thomas, Thomas R. Fanshawe, and Tim Lancaster. 2016. <span>“Nicotine Receptor Partial Agonists for Smoking Cessation.”</span> <em>The Cochrane Database of Systematic Reviews</em>, no. 5 (May): CD006103. <a href="https://doi.org/10.1002/14651858.CD006103.pub7">https://doi.org/10.1002/14651858.CD006103.pub7</a>.
</div>
<div id="ref-colhoun2004" class="csl-entry" role="doc-biblioentry">
Colhoun, Helen M., D. John Betteridge, Paul N. Durrington, Graham A. Hitman, H. Andrew W. Neil, Shona J. Livingstone, Margaret J. Thomason, et al. 2004. <span>“Primary Prevention of Cardiovascular Disease with Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo-Controlled Trial.”</span> <em>Lancet (London, England)</em> 364 (9435): 685–96. <a href="https://doi.org/10.1016/S0140-6736(04)16895-5">https://doi.org/10.1016/S0140-6736(04)16895-5</a>.
</div>
<div id="ref-collaborationCollaborativeMetaanalysisRandomised2002" class="csl-entry" role="doc-biblioentry">
Collaboration, Antithrombotic Trialists’. 2002. <span>“<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64503">Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients</a>.”</span> <em>BMJ : British Medical Journal</em> 324 (7329): 71–86.
</div>
<div id="ref-antithrombotictrialists2009" class="csl-entry" role="doc-biblioentry">
Collaboration, Antithrombotic Trialists’(ATT), Colin Baigent, Lisa Blackwell, Rory Collins, Jonathan Emberson, Jon Godwin, Richard Peto, et al. 2009. <span>“Aspirin in the Primary and Secondary Prevention of Vascular Disease: Collaborative Meta-Analysis of Individual Participant Data from Randomised Trials.”</span> <em>Lancet (London, England)</em> 373 (9678): 1849–60. <a href="https://doi.org/10.1016/S0140-6736(09)60503-1">https://doi.org/10.1016/S0140-6736(09)60503-1</a>.
</div>
<div id="ref-cholesteroltreatmenttrialists2008" class="csl-entry" role="doc-biblioentry">
Collaborators, Cholesterol Treatment Trialists’(CTT), P. M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto, J. Armitage, and C. Baigent. 2008. <span>“Efficacy of Cholesterol-Lowering Therapy in 18,686 People with Diabetes in 14 Randomised Trials of Statins: A Meta-Analysis.”</span> <em>Lancet (London, England)</em> 371 (9607): 117–25. <a href="https://doi.org/10.1016/S0140-6736(08)60104-X">https://doi.org/10.1016/S0140-6736(08)60104-X</a>.
</div>
<div id="ref-capriesteeringcommitteeRandomisedBlindedTrial1996" class="csl-entry" role="doc-biblioentry">
Committee, CAPRIE Steering. 1996. <span>“A Randomised, Blinded, Trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (<span>CAPRIE</span>).”</span> <em>The Lancet</em> 348 (9038): 1329–39. <a href="https://doi.org/10.1016/S0140-6736(96)09457-3">https://doi.org/10.1016/S0140-6736(96)09457-3</a>.
</div>
<div id="ref-conteGlobalVascularGuidelines2019a" class="csl-entry" role="doc-biblioentry">
Conte, Michael S., Andrew W. Bradbury, Philippe Kolh, John V. White, Florian Dick, Robert Fitridge, Joseph L Mills, Jean-Baptiste Ricco, Kalkunte R. Suresh, and M. Hassan Murad. 2019. <span>“Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia.”</span> <em>European Journal of Vascular and Endovascular Surgery : The Official Journal of the European Society for Vascular Surgery</em> 58 (1 Suppl): S1–S109.e33. <a href="https://doi.org/10.1016/j.ejvs.2019.05.006">https://doi.org/10.1016/j.ejvs.2019.05.006</a>.
</div>
<div id="ref-conteSocietyVascularSurgery2015" class="csl-entry" role="doc-biblioentry">
Conte, Michael S., Frank B. Pomposelli, Daniel G. Clair, Patrick J. Geraghty, James F. McKinsey, Joseph L. Mills, Gregory L. Moneta, M. Hassan Murad, Richard J. Powell, Amy B. Reed, Andres Schanzer, et al. 2015. <span>“Society for <span>Vascular Surgery</span> Practice Guidelines for Atherosclerotic Occlusive Disease of the Lower Extremities: <span>Management</span> of Asymptomatic Disease and Claudication.”</span> <em>Journal of Vascular Surgery</em> 61 (3): 2S–41S.e1. <a href="https://doi.org/10.1016/j.jvs.2014.12.009">https://doi.org/10.1016/j.jvs.2014.12.009</a>.
</div>
<div id="ref-conte2015" class="csl-entry" role="doc-biblioentry">
Conte, Michael S., Frank B. Pomposelli, Daniel G. Clair, Patrick J. Geraghty, James F. McKinsey, Joseph L. Mills, Gregory L. Moneta, M. Hassan Murad, Richard J. Powell, Amy B. Reed, and et al. 2015. <span>“Society for Vascular Surgery Practice Guidelines for Atherosclerotic Occlusive Disease of the Lower Extremities: Management of Asymptomatic Disease and Claudication.”</span> <em>Journal of Vascular Surgery</em> 61 (3): 2S–41S.e1. <a href="https://doi.org/10.1016/j.jvs.2014.12.009">https://doi.org/10.1016/j.jvs.2014.12.009</a>.
</div>
<div id="ref-dangelo1997" class="csl-entry" role="doc-biblioentry">
D’Angelo, A., and J. Selhub. 1997. <span>“Homocysteine and Thrombotic Disease.”</span> <em>Blood</em> 90 (1): 1–11.
</div>
<div id="ref-diehm2004" class="csl-entry" role="doc-biblioentry">
Diehm, Curt, Stefan Lange, Hans Joachim Trampisch, Roman Haberl, Harald Darius, Berndt von Stritzky, David Pittrow, Gerhart Tepohl, Jens Rainer Allenberg, and GetABI Study Group. 2004. <span>“Relationship Between Lipid Parameters and the Presence of Peripheral Arterial Disease in Elderly Patients.”</span> <em>Current Medical Research and Opinion</em> 20 (12): 1873–75. <a href="https://doi.org/10.1185/030079904x12780">https://doi.org/10.1185/030079904x12780</a>.
</div>
<div id="ref-eikelboom2017" class="csl-entry" role="doc-biblioentry">
Eikelboom, John W., Stuart J. Connolly, Jackie Bosch, Gilles R. Dagenais, Robert G. Hart, Olga Shestakovska, Rafael Diaz, et al. 2017. <span>“Rivaroxaban with or Without Aspirin in Stable Cardiovascular Disease.”</span> <em>The New England Journal of Medicine</em> 377 (14): 1319–30. <a href="https://doi.org/10.1056/NEJMoa1709118">https://doi.org/10.1056/NEJMoa1709118</a>.
</div>
<div id="ref-emdin2015" class="csl-entry" role="doc-biblioentry">
Emdin, Connor A., Simon G. Anderson, Thomas Callender, Nathalie Conrad, Gholamreza Salimi-Khorshidi, Hamid Mohseni, Mark Woodward, and Kazem Rahimi. 2015. <span>“Usual Blood Pressure, Peripheral Arterial Disease, and Vascular Risk: Cohort Study of 4.2 Million Adults.”</span> <em>BMJ (Clinical Research Ed.)</em> 351 (September): h4865. <a href="https://doi.org/10.1136/bmj.h4865">https://doi.org/10.1136/bmj.h4865</a>.
</div>
<div id="ref-fakhry2015" class="csl-entry" role="doc-biblioentry">
Fakhry, Farzin, Sandra Spronk, Lijckle van der Laan, Jan J. Wever, Joep A. W. Teijink, Wolter H. Hoffmann, Taco M. Smits, et al. 2015. <span>“Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial.”</span> <em>JAMA</em> 314 (18): 1936–44. <a href="https://doi.org/10.1001/jama.2015.14851">https://doi.org/10.1001/jama.2015.14851</a>.
</div>
<div id="ref-fakhry2013" class="csl-entry" role="doc-biblioentry">
Fakhry, F., E. V. Rouwet, P. T. den Hoed, M. G. M. Hunink, and S. Spronk. 2013. <span>“Long-Term Clinical Effectiveness of Supervised Exercise Therapy Versus Endovascular Revascularization for Intermittent Claudication from a Randomized Clinical Trial.”</span> <em>The British Journal of Surgery</em> 100 (9): 1164–71. <a href="https://doi.org/10.1002/bjs.9207">https://doi.org/10.1002/bjs.9207</a>.
</div>
<div id="ref-fontaineSurgicalTreatmentPeripheral1954" class="csl-entry" role="doc-biblioentry">
Fontaine, R., M. Kim, and R. Kieny. 1954. <span>“<a href="https://www.ncbi.nlm.nih.gov/pubmed/14366554"><span>[Surgical treatment of peripheral circulation disorders]</span></a>.”</span> <em>Helvetica Chirurgica Acta</em> 21 (5-6): 499–533.
</div>
<div id="ref-fowkesEdinburghArteryStudy1991" class="csl-entry" role="doc-biblioentry">
Fowkes, F G R, E Housley, E H H Cawood, C C A Macintyre, C V Ruckley, and R J Prescott. 1991. <span>“Edinburgh <span>Artery Study</span>: <span>Prevalence</span> of <span>Asymptomatic</span> and <span>Symptomatic Peripheral Arterial Disease</span> in the <span>General Population</span>.”</span> <em>International Journal of Epidemiology</em> 20 (2): 384–92. <a href="https://doi.org/10.1093/ije/20.2.384">https://doi.org/10.1093/ije/20.2.384</a>.
</div>
<div id="ref-fowkesAspirinPreventionCardiovascular2010" class="csl-entry" role="doc-biblioentry">
Fowkes, F. Gerald R. 2010. <span>“Aspirin for <span>Prevention</span> of <span>Cardiovascular Events</span> in a <span>General Population Screened</span> for a <span>Low Ankle Brachial IndexA Randomized Controlled Trial</span>.”</span> <em>JAMA</em> 303 (9): 841. <a href="https://doi.org/10.1001/jama.2010.221">https://doi.org/10.1001/jama.2010.221</a>.
</div>
<div id="ref-frederick2010" class="csl-entry" role="doc-biblioentry">
Frederick, Michael, John Newman, and Jeffrey Kohlwes. 2010. <span>“Leriche Syndrome.”</span> <em>Journal of General Internal Medicine</em> 25 (10): 1102–4. <a href="https://doi.org/10.1007/s11606-010-1412-z">https://doi.org/10.1007/s11606-010-1412-z</a>.
</div>
<div id="ref-geraldes2010" class="csl-entry" role="doc-biblioentry">
Geraldes, Pedro, and George L. King. 2010. <span>“Activation of Protein Kinase c Isoforms and Its Impact on Diabetic Complications.”</span> <em>Circulation Research</em> 106 (8): 1319–31. <a href="https://doi.org/10.1161/CIRCRESAHA.110.217117">https://doi.org/10.1161/CIRCRESAHA.110.217117</a>.
</div>
<div id="ref-gordonPredispositionAtherosclerosisHead1972" class="csl-entry" role="doc-biblioentry">
Gordon, T., and W. B. Kannel. 1972. <span>“<a href="https://www.ncbi.nlm.nih.gov/pubmed/4261853">Predisposition to Atherosclerosis in the Head, Heart, and Legs. <span>The Framingham</span> Study</a>.”</span> <em>JAMA</em> 221 (7): 661–66.
</div>
<div id="ref-grenon2012" class="csl-entry" role="doc-biblioentry">
Grenon, S. Marlene, Millie Hughes-Fulford, Joseph Rapp, and Michael S. Conte. 2012. <span>“Polyunsaturated Fatty Acids and Peripheral Artery Disease.”</span> <em>Vascular Medicine (London, England)</em> 17 (1): 51–63. <a href="https://doi.org/10.1177/1358863X11429175">https://doi.org/10.1177/1358863X11429175</a>.
</div>
<div id="ref-heartprotectionstudycollaborativegroupRandomizedTrialEffects2007" class="csl-entry" role="doc-biblioentry">
Group, Heart Protection Study Collaborative. 2007. <span>“Randomized Trial of the Effects of Cholesterol-Lowering with Simvastatin on Peripheral Vascular and Other Major Vascular Outcomes in 20,536 People with Peripheral Arterial Disease and Other High-Risk Conditions.”</span> <em>Journal of Vascular Surgery</em> 45 (4): 645–654.e1. <a href="https://doi.org/10.1016/j.jvs.2006.12.054">https://doi.org/10.1016/j.jvs.2006.12.054</a>.
</div>
<div id="ref-poisestudygroup2008" class="csl-entry" role="doc-biblioentry">
Group, POISE Study, P. J. Devereaux, Homer Yang, Salim Yusuf, Gordon Guyatt, Kate Leslie, Juan Carlos Villar, et al. 2008. <span>“Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial.”</span> <em>Lancet (London, England)</em> 371 (9627): 1839–47. <a href="https://doi.org/10.1016/S0140-6736(08)60601-7">https://doi.org/10.1016/S0140-6736(08)60601-7</a>.
</div>
<div id="ref-hackam2003" class="csl-entry" role="doc-biblioentry">
Hackam, Daniel G., and Sonia S. Anand. 2003. <span>“Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence.”</span> <em>JAMA</em> 290 (7): 932–40. <a href="https://doi.org/10.1001/jama.290.7.932">https://doi.org/10.1001/jama.290.7.932</a>.
</div>
<div id="ref-hagemanSupervisedExerciseTherapy2018" class="csl-entry" role="doc-biblioentry">
Hageman, David, Hugo JP Fokkenrood, Lindy NM Gommans, Marijn ML van den Houten, and Joep AW Teijink. 2018. <span>“Supervised Exercise Therapy Versus Home-Based Exercise Therapy Versus Walking Advice for Intermittent Claudication.”</span> <em>The Cochrane Database of Systematic Reviews</em> 2018 (4): CD005263. <a href="https://doi.org/10.1002/14651858.CD005263.pub4">https://doi.org/10.1002/14651858.CD005263.pub4</a>.
</div>
<div id="ref-higashi2009" class="csl-entry" role="doc-biblioentry">
Higashi, Yukihito, Kensuke Noma, Masao Yoshizumi, and Yasuki Kihara. 2009. <span>“Endothelial Function and Oxidative Stress in Cardiovascular Diseases.”</span> <em>Circulation Journal: Official Journal of the Japanese Circulation Society</em> 73 (3): 411–18. <a href="https://doi.org/10.1253/circj.cj-08-1102">https://doi.org/10.1253/circj.cj-08-1102</a>.
</div>
<div id="ref-hiltunen1998" class="csl-entry" role="doc-biblioentry">
Hiltunen, T. P., J. S. Luoma, T. Nikkari, and S. Ylä-Herttuala. 1998. <span>“Expression of LDL Receptor, VLDL Receptor, LDL Receptor-Related Protein, and Scavenger Receptor in Rabbit Atherosclerotic Lesions: Marked Induction of Scavenger Receptor and VLDL Receptor Expression During Lesion Development.”</span> <em>Circulation</em> 97 (11): 1079–86. <a href="https://doi.org/10.1161/01.cir.97.11.1079">https://doi.org/10.1161/01.cir.97.11.1079</a>.
</div>
<div id="ref-hughes2014" class="csl-entry" role="doc-biblioentry">
Hughes, John R., Lindsay F. Stead, Jamie Hartmann-Boyce, Kate Cahill, and Tim Lancaster. 2014. <span>“Antidepressants for Smoking Cessation.”</span> <em>The Cochrane Database of Systematic Reviews</em>, no. 1 (January): CD000031. <a href="https://doi.org/10.1002/14651858.CD000031.pub4">https://doi.org/10.1002/14651858.CD000031.pub4</a>.
</div>
<div id="ref-hussain2018" class="csl-entry" role="doc-biblioentry">
Hussain, Mohamad A., Mohammed Al-Omran, Mark A. Creager, Sonia S. Anand, Subodh Verma, and Deepak L. Bhatt. 2018. <span>“Antithrombotic Therapy for Peripheral&nbsp;Artery Disease: Recent Advances.”</span> <em>Journal of the American College of Cardiology</em> 71 (21): 2450–67. <a href="https://doi.org/10.1016/j.jacc.2018.03.483">https://doi.org/10.1016/j.jacc.2018.03.483</a>.
</div>
<div id="ref-itoga2018" class="csl-entry" role="doc-biblioentry">
Itoga, Nathan K., Daniel S. Tawfik, Charles K. Lee, Satoshi Maruyama, Nicholas J. Leeper, and Tara I. Chang. 2018. <span>“Association of Blood Pressure Measurements with Peripheral Artery Disease Events.”</span> <em>Circulation</em> 138 (17): 1805–14. <a href="https://doi.org/10.1161/CIRCULATIONAHA.118.033348">https://doi.org/10.1161/CIRCULATIONAHA.118.033348</a>.
</div>
<div id="ref-jha2019" class="csl-entry" role="doc-biblioentry">
Jha, Manish K., Arman Qamar, Muthiah Vaduganathan, Dennis S. Charney, and James W. Murrough. 2019. <span>“Screening and Management of Depression in Patients with Cardiovascular Disease: JACC&nbsp;State-of-the-Art Review.”</span> <em>Journal of the American College of Cardiology</em> 73 (14): 1827–45. <a href="https://doi.org/10.1016/j.jacc.2019.01.041">https://doi.org/10.1016/j.jacc.2019.01.041</a>.
</div>
<div id="ref-kannelUpdateEpidemiologicFeatures1985" class="csl-entry" role="doc-biblioentry">
Kannel, W. B., and D. L. McGee. 1985. <span>“Update on Some Epidemiologic Features of Intermittent Claudication: The <span>Framingham Study</span>.”</span> <em>Journal of the American Geriatrics Society</em> 33 (1): 13–18. <a href="https://doi.org/10.1111/j.1532-5415.1985.tb02853.x">https://doi.org/10.1111/j.1532-5415.1985.tb02853.x</a>.
</div>
<div id="ref-katsanos2018" class="csl-entry" role="doc-biblioentry">
Katsanos, Konstantinos, Stavros Spiliopoulos, Panagiotis Kitrou, Miltiadis Krokidis, and Dimitrios Karnabatidis. 2018. <span>“Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.”</span> <em>Journal of the American Heart Association</em> 7 (24): e011245. <a href="https://doi.org/10.1161/JAHA.118.011245">https://doi.org/10.1161/JAHA.118.011245</a>.
</div>
<div id="ref-kayssi2019" class="csl-entry" role="doc-biblioentry">
KAYSSI, AHMED, LEE C. ROGERS, and RICHARD F. NEVILLE. 2019. <span>“113: General Considerations of Diabetic Foot Ulcers.”</span> In <em>Rutherford’s Vascular Surgery and Endovascular Therapy</em>. Elsevier Inc. <a href="https://doi.org/10.1016/B978-0-323-42791-3.00113-4">https://doi.org/10.1016/B978-0-323-42791-3.00113-4</a>.
</div>
<div id="ref-keen2014" class="csl-entry" role="doc-biblioentry">
Keen, Helen I., Janakan Krishnarajah, Timothy R. Bates, and Gerald F. Watts. 2014. <span>“Statin Myopathy: The Fly in the Ointment for the Prevention of Cardiovascular Disease in the 21st Century?”</span> <em>Expert Opinion on Drug Safety</em> 13 (9): 1227–39. <a href="https://doi.org/10.1517/14740338.2014.937422">https://doi.org/10.1517/14740338.2014.937422</a>.
</div>
<div id="ref-khandanpour2009" class="csl-entry" role="doc-biblioentry">
Khandanpour, N., Y. K. Loke, F. J. Meyer, B. Jennings, and M. P. Armon. 2009. <span>“Homocysteine and Peripheral Arterial Disease: Systematic Review and Meta-Analysis.”</span> <em>European Journal of Vascular and Endovascular Surgery: The Official Journal of the European Society for Vascular Surgery</em> 38 (3): 316–22. <a href="https://doi.org/10.1016/j.ejvs.2009.05.007">https://doi.org/10.1016/j.ejvs.2009.05.007</a>.
</div>
<div id="ref-kris-etherton2002" class="csl-entry" role="doc-biblioentry">
Kris-Etherton, Penny M., William S. Harris, Lawrence J. Appel, and American Heart Association. Nutrition Committee. 2002. <span>“Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease.”</span> <em>Circulation</em> 106 (21): 2747–57. <a href="https://doi.org/10.1161/01.cir.0000038493.65177.94">https://doi.org/10.1161/01.cir.0000038493.65177.94</a>.
</div>
<div id="ref-lajoie2019" class="csl-entry" role="doc-biblioentry">
Lajoie, Lidie. 2019. <span>“12. Atherosclerotic Risk Factors: Diabetes.”</span> In <em>Rutherfords Vascular Surgery and Endovascular Therapy</em>, 12. Elsevier Inc.
</div>
<div id="ref-laneExerciseIntermittentClaudication2017" class="csl-entry" role="doc-biblioentry">
Lane, Risha, Amy Harwood, Lorna Watson, and Gillian C Leng. 2017. <span>“Exercise for Intermittent Claudication.”</span> <em>The Cochrane Database of Systematic Reviews</em> 2017 (12): CD000990. <a href="https://doi.org/10.1002/14651858.CD000990.pub4">https://doi.org/10.1002/14651858.CD000990.pub4</a>.
</div>
<div id="ref-langlois2018" class="csl-entry" role="doc-biblioentry">
Langlois, Michel R., and Børge G. Nordestgaard. 2018. <span>“Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?”</span> <em>Current Cardiology Reports</em> 20 (10): 88. <a href="https://doi.org/10.1007/s11886-018-1036-1">https://doi.org/10.1007/s11886-018-1036-1</a>.
</div>
<div id="ref-lendEdinburghClaudicationQuestionnaire1992" class="csl-entry" role="doc-biblioentry">
Lend, G. C., and F. G. R. Fowkes. 1992. <span>“The <span>Edinburgh Claudication Questionnaire</span>: <span>An</span> Improved Version of the <span>WHO</span>/<span>Rose</span> Questionnaire for Use in Epidemiological Surveys.”</span> <em>Journal of Clinical Epidemiology</em> 45 (10): 1101–9. <a href="https://doi.org/10.1016/0895-4356(92)90150-L">https://doi.org/10.1016/0895-4356(92)90150-L</a>.
</div>
<div id="ref-lepäntalo2011" class="csl-entry" role="doc-biblioentry">
Lepäntalo, M., J. Apelqvist, C. Setacci, J.-B. Ricco, G. de Donato, F. Becker, H. Robert-Ebadi, et al. 2011. <span>“Chapter v: Diabetic Foot.”</span> <em>European Journal of Vascular and Endovascular Surgery</em> 42 (December): S60–74. <a href="https://doi.org/10.1016/S1078-5884(11)60012-9">https://doi.org/10.1016/S1078-5884(11)60012-9</a>.
</div>
<div id="ref-leriche1948" class="csl-entry" role="doc-biblioentry">
Leriche, René, and André Morel. 1948. <span>“The Syndrome of Thrombotic Obliteration of the Aortic Bifurcation.”</span> <em>Annals of Surgery</em> 127 (2): 193–206. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513778/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513778/</a>.
</div>
<div id="ref-liebman2019" class="csl-entry" role="doc-biblioentry">
Liebman, Howard A. 2019. <span>“38. Hypercoagulable States.”</span> In <em>Rutherford’s Vascular Surgery and Endovascular Therapy</em>, 19. Elsevier Inc.
</div>
<div id="ref-mahmoodFraminghamHeartStudy2014" class="csl-entry" role="doc-biblioentry">
Mahmood, Syed S., Daniel Levy, Ramachandran S. Vasan, and Thomas J. Wang. 2014. <span>“The <span>Framingham Heart Study</span> and the <span>Epidemiology</span> of <span>Cardiovascular Diseases</span>: <span>A Historical Perspective</span>.”</span> <em>Lancet</em> 383 (9921): 999–1008. <a href="https://doi.org/10.1016/S0140-6736(13)61752-3">https://doi.org/10.1016/S0140-6736(13)61752-3</a>.
</div>
<div id="ref-mcdermott2016" class="csl-entry" role="doc-biblioentry">
McDermott, Mary M., Jack M. Guralnik, Lu Tian, Melina R. Kibbe, Luigi Ferrucci, Lihui Zhao, Kiang Liu, Yihua Liao, Ying Gao, and Michael H. Criqui. 2016. <span>“Incidence and Prognostic Significance of Depressive Symptoms in&nbsp;Peripheral Artery Disease.”</span> <em>Journal of the American Heart Association</em> 5 (3): e002959. <a href="https://doi.org/10.1161/JAHA.115.002959">https://doi.org/10.1161/JAHA.115.002959</a>.
</div>
<div id="ref-mcgill2000" class="csl-entry" role="doc-biblioentry">
McGill, H. C., C. A. McMahan, A. W. Zieske, R. E. Tracy, G. T. Malcom, E. E. Herderick, and J. P. Strong. 2000. <span>“Association of Coronary Heart Disease Risk Factors with Microscopic Qualities of Coronary Atherosclerosis in Youth.”</span> <em>Circulation</em> 102 (4): 374–79. <a href="https://doi.org/10.1161/01.cir.102.4.374">https://doi.org/10.1161/01.cir.102.4.374</a>.
</div>
<div id="ref-millsSocietyVascularSurgery2014a" class="csl-entry" role="doc-biblioentry">
Mills, Joseph L., Michael S. Conte, David G. Armstrong, Frank B. Pomposelli, Andres Schanzer, Anton N. Sidawy, and George Andros. 2014. <span>“The <span>Society</span> for <span>Vascular Surgery Lower Extremity Threatened Limb Classification System</span>: <span>Risk</span> Stratification Based on <span>Wound</span>, <span>Ischemia</span>, and Foot <span>Infection</span> (<span>WIfI</span>).”</span> <em>Journal of Vascular Surgery</em> 59 (1): 220–234.e2. <a href="https://doi.org/10.1016/j.jvs.2013.08.003">https://doi.org/10.1016/j.jvs.2013.08.003</a>.
</div>
<div id="ref-murphy2012" class="csl-entry" role="doc-biblioentry">
Murphy, Timothy P., Donald E. Cutlip, Judith G. Regensteiner, Emile R. Mohler, David J. Cohen, Matthew R. Reynolds, Joseph M. Massaro, et al. 2012. <span>“Supervised Exercise Versus Primary Stenting for Claudication Resulting from Aortoiliac Peripheral Artery Disease: Six-Month Outcomes from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Study.”</span> <em>Circulation</em> 125 (1): 130–39. <a href="https://doi.org/10.1161/CIRCULATIONAHA.111.075770">https://doi.org/10.1161/CIRCULATIONAHA.111.075770</a>.
</div>
<div id="ref-murphy2015" class="csl-entry" role="doc-biblioentry">
———, et al. 2015. <span>“Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery Disease: The CLEVER Study.”</span> <em>Journal of the American College of Cardiology</em> 65 (10): 999–1009. <a href="https://doi.org/10.1016/j.jacc.2014.12.043">https://doi.org/10.1016/j.jacc.2014.12.043</a>.
</div>
<div id="ref-nadeauReliabilityDifferentiatingNeurogenic2013" class="csl-entry" role="doc-biblioentry">
Nadeau, Mélissa, M. Patricia Rosas-Arellano, Kevin R. Gurr, Stewart I. Bailey, David C. Taylor, Ruby Grewal, D. Kirk Lawlor, and Chris S. Bailey. 2013. <span>“The Reliability of Differentiating Neurogenic Claudication from Vascular Claudication Based on Symptomatic Presentation.”</span> <em>Canadian Journal of Surgery</em> 56 (6): 372–77. <a href="https://doi.org/10.1503/cjs.016512">https://doi.org/10.1503/cjs.016512</a>.
</div>
<div id="ref-nicolaiReliabilityTreadmillTesting2009" class="csl-entry" role="doc-biblioentry">
Nicolaï, Saskia P. A., Wolfgang Viechtbauer, Lotte M. Kruidenier, Math J. J. M. Candel, Martin H. Prins, and Joep A. W. Teijink. 2009. <span>“Reliability of Treadmill Testing in Peripheral Arterial Disease: <span>A</span> Meta-Regression Analysis.”</span> <em>Journal of Vascular Surgery</em> 50 (2): 322–29. <a href="https://doi.org/10.1016/j.jvs.2009.01.042">https://doi.org/10.1016/j.jvs.2009.01.042</a>.
</div>
<div id="ref-norgren2007" class="csl-entry" role="doc-biblioentry">
Norgren, L., W. R. Hiatt, J. A. Dormandy, M. R. Nehler, K. A. Harris, and F. G. R. Fowkes. 2007. <span>“Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).”</span> <em>Journal of Vascular Surgery</em> 45 (1): S5–67. <a href="https://doi.org/10.1016/j.jvs.2006.12.037">https://doi.org/10.1016/j.jvs.2006.12.037</a>.
</div>
<div id="ref-ourielCriticalEvaluationStress1982" class="csl-entry" role="doc-biblioentry">
Ouriel, K., A. E. McDonnell, C. E. Metz, and C. K. Zarins. 1982. <span>“<a href="https://www.ncbi.nlm.nih.gov/pubmed/7079971">Critical Evaluation of Stress Testing in the Diagnosis of Peripheral Vascular Disease</a>.”</span> <em>Surgery</em> 91 (6): 686–93.
</div>
<div id="ref-owens2019" class="csl-entry" role="doc-biblioentry">
Owens, Christopher D. 2019. <span>“4: Atherosclerosis.”</span> In <em>Rutherford’s Vascular Surgery and Endovascular Therapy</em>, 14. Elsevier Inc.
</div>
<div id="ref-piper2014" class="csl-entry" role="doc-biblioentry">
Piper, Margaret A., Corinne V. Evans, Brittany U. Burda, Karen L. Margolis, Elizabeth O’Connor, Ning Smith, Elizabeth Webber, Leslie A. Perdue, Keshia D. Bigler, and Evelyn P. Whitlock. 2014. <em>Screening for High Blood Pressure in Adults: A Systematic Evidence Review for the u.s. Preventive Services Task Force</em>. U.s. Preventive Services Task Force Evidence Syntheses, Formerly Systematic Evidence Reviews. Agency for Healthcare Research; Quality (US). <a href="http://www.ncbi.nlm.nih.gov/books/NBK269495/">http://www.ncbi.nlm.nih.gov/books/NBK269495/</a>.
</div>
<div id="ref-ramirez2018" class="csl-entry" role="doc-biblioentry">
Ramirez, Joel L., Laura M. Drudi, and S. Marlene Grenon. 2018. <span>“Review of Biologic and Behavioral Risk Factors Linking Depression and Peripheral Artery Disease.”</span> <em>Vascular Medicine (London, England)</em> 23 (5): 478–88. <a href="https://doi.org/10.1177/1358863X18773161">https://doi.org/10.1177/1358863X18773161</a>.
</div>
<div id="ref-ratchford2011" class="csl-entry" role="doc-biblioentry">
Ratchford, Elizabeth V., and James H. Black. 2011. <span>“Approach to Smoking Cessation in the Patient with Vascular Disease.”</span> <em>Current Treatment Options in Cardiovascular Medicine</em> 13 (2): 91–102. <a href="https://doi.org/10.1007/s11936-011-0109-x">https://doi.org/10.1007/s11936-011-0109-x</a>.
</div>
<div id="ref-regensteiner2015" class="csl-entry" role="doc-biblioentry">
Regensteiner, Judith G., Sherita Golden, Amy G. Huebschmann, Elizabeth Barrett-Connor, Alice Y. Chang, Deborah Chyun, Caroline S. Fox, et al. 2015. <span>“Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement from the American Heart Association.”</span> <em>Circulation</em> 132 (25): 2424–47. <a href="https://doi.org/10.1161/CIR.0000000000000343">https://doi.org/10.1161/CIR.0000000000000343</a>.
</div>
<div id="ref-ridker2008" class="csl-entry" role="doc-biblioentry">
Ridker, Paul M., Eleanor Danielson, Francisco A. H. Fonseca, Jacques Genest, Antonio M. Gotto, John J. P. Kastelein, Wolfgang Koenig, et al. 2008. <span>“Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated c-Reactive Protein.”</span> <em>The New England Journal of Medicine</em> 359 (21): 2195–2207. <a href="https://doi.org/10.1056/NEJMoa0807646">https://doi.org/10.1056/NEJMoa0807646</a>.
</div>
<div id="ref-rooke2013" class="csl-entry" role="doc-biblioentry">
Rooke, Thom W., Alan T. Hirsch, Sanjay Misra, Anton N. Sidawy, Joshua A. Beckman, Laura Findeiss, Jafar Golzarian, et al. 2013. <span>“Management of Patients with Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.”</span> <em>Journal of the American College of Cardiology</em> 61 (14): 1555–70. <a href="https://doi.org/10.1016/j.jacc.2013.01.004">https://doi.org/10.1016/j.jacc.2013.01.004</a>.
</div>
<div id="ref-roseDiagnosisIschaemicHeart1962" class="csl-entry" role="doc-biblioentry">
Rose, G. A. 1962. <span>“<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2555832">The Diagnosis of Ischaemic Heart Pain and Intermittent Claudication in Field Surveys</a>.”</span> <em>Bulletin of the World Health Organization</em> 27 (6): 645–58.
</div>
<div id="ref-rutherfordRecommendedStandardsReports1997" class="csl-entry" role="doc-biblioentry">
Rutherford, Robert B., J.Dennis Baker, Calvin Ernst, K.Wayne Johnston, John M. Porter, Sam Ahn, and Darrell N. Jones. 1997. <span>“Recommended Standards for Reports Dealing with Lower Extremity Ischemia: <span>Revised</span> Version.”</span> <em>Journal of Vascular Surgery</em> 26 (3): 517–38. <a href="https://doi.org/10.1016/S0741-5214(97)70045-4">https://doi.org/10.1016/S0741-5214(97)70045-4</a>.
</div>
<div id="ref-saxon2016" class="csl-entry" role="doc-biblioentry">
Saxon, David R., and Robert H. Eckel. 2016. <span>“Statin Intolerance: A Literature Review and Management Strategies.”</span> <em>Progress in Cardiovascular Diseases</em> 59 (2): 153–64. <a href="https://doi.org/10.1016/j.pcad.2016.07.009">https://doi.org/10.1016/j.pcad.2016.07.009</a>.
</div>
<div id="ref-selvin2006" class="csl-entry" role="doc-biblioentry">
Selvin, Elizabeth, Keattiyoat Wattanakit, Michael W. Steffes, Josef Coresh, and A. Richey Sharrett. 2006. <span>“HbA1c and Peripheral Arterial Disease in Diabetes: The Atherosclerosis Risk in Communities Study.”</span> <em>Diabetes Care</em> 29 (4): 877–82. <a href="https://doi.org/10.2337/diacare.29.04.06.dc05-2018">https://doi.org/10.2337/diacare.29.04.06.dc05-2018</a>.
</div>
<div id="ref-setacci2012" class="csl-entry" role="doc-biblioentry">
Setacci, C., G. Galzerano, F. Setacci, G. De Donato, P. Sirignano, V. Kamargianni, A. Cannizzaro, and A. Cappelli. 2012. <span>“Endovascular Approach to Leriche Syndrome.”</span> <em>The Journal of Cardiovascular Surgery</em> 53 (3): 301–6.
</div>
<div id="ref-siscovick2017" class="csl-entry" role="doc-biblioentry">
Siscovick, David S., Thomas A. Barringer, Amanda M. Fretts, Jason H. Y. Wu, Alice H. Lichtenstein, Rebecca B. Costello, Penny M. Kris-Etherton, et al. 2017. <span>“Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory from the American Heart Association.”</span> <em>Circulation</em> 135 (15): e867–84. <a href="https://doi.org/10.1161/CIR.0000000000000482">https://doi.org/10.1161/CIR.0000000000000482</a>.
</div>
<div id="ref-stamler1993" class="csl-entry" role="doc-biblioentry">
Stamler, J., O. Vaccaro, J. D. Neaton, and D. Wentworth. 1993. <span>“Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial.”</span> <em>Diabetes Care</em> 16 (2): 434–44. <a href="https://doi.org/10.2337/diacare.16.2.434">https://doi.org/10.2337/diacare.16.2.434</a>.
</div>
<div id="ref-stevensSystematicReviewEfficacy2012" class="csl-entry" role="doc-biblioentry">
Stevens, J W, E Simpson, S Harnan, H Squires, Y Meng, S Thomas, J Michaels, and G Stansby. 2012. <span>“Systematic Review of the Efficacy of Cilostazol, Naftidrofuryl Oxalate and Pentoxifylline for the Treatment of Intermittent Claudication.”</span> <em>British Journal of Surgery</em> 99 (12): 1630–38. <a href="https://doi.org/10.1002/bjs.8895">https://doi.org/10.1002/bjs.8895</a>.
</div>
<div id="ref-stone21VascularLaboratory2019" class="csl-entry" role="doc-biblioentry">
Stone, Patrick A, and Stephen M Hass. 2019. <span>“21. <span>Vascular Laboratory</span>: <span>Arterial Duplex Scanning</span>.”</span> In <em>Rutherford’s <span>Vascular Surgery</span> and <span>Endovascular Therapy</span></em>, Ninth. <span>Elsevier Inc.</span> <a href="https://doi.org/10.1016/B978-0-323-42791-3.00021-9">https://doi.org/10.1016/B978-0-323-42791-3.00021-9</a>.
</div>
<div id="ref-strandnessHemodynamicsSurgeons1975a" class="csl-entry" role="doc-biblioentry">
Strandness, D. E., and David S. Sumner. 1975. <em>Hemodynamics for Surgeons</em>. Modern Surgical Monographs. <span>New York</span>: <span>Grune &amp; Stratton</span>.
</div>
<div id="ref-strobl2013" class="csl-entry" role="doc-biblioentry">
Strobl, Frederik F., Klaus Brechtel, Jörg Schmehl, Thomas Zeller, Maximilian F. Reiser, Claus D. Claussen, and Gunnar Tepe. 2013. <span>“Twelve-Month Results of a Randomized Trial Comparing Mono with Dual Antiplatelet Therapy in Endovascularly Treated Patients with Peripheral Artery Disease.”</span> <em>Journal of Endovascular Therapy: An Official Journal of the International Society of Endovascular Specialists</em> 20 (5): 699–706. <a href="https://doi.org/10.1583/13-4275MR.1">https://doi.org/10.1583/13-4275MR.1</a>.
</div>
<div id="ref-tepe2012" class="csl-entry" role="doc-biblioentry">
Tepe, Gunnar, Rüdiger Bantleon, Klaus Brechtel, Jörg Schmehl, Thomas Zeller, Claus D. Claussen, and Frederik F. Strobl. 2012. <span>“Management of Peripheral Arterial Interventions with Mono or Dual Antiplatelet Therapy–the MIRROR Study: A Randomised and Double-Blinded Clinical Trial.”</span> <em>European Radiology</em> 22 (9): 1998–2006. <a href="https://doi.org/10.1007/s00330-012-2441-2">https://doi.org/10.1007/s00330-012-2441-2</a>.
</div>
<div id="ref-thomsen2014" class="csl-entry" role="doc-biblioentry">
Thomsen, Thordis, Nete Villebro, and Ann Merete Møller. 2014. <span>“Interventions for Preoperative Smoking Cessation.”</span> <em>The Cochrane Database of Systematic Reviews</em>, no. 3 (March): CD002294. <a href="https://doi.org/10.1002/14651858.CD002294.pub4">https://doi.org/10.1002/14651858.CD002294.pub4</a>.
</div>
<div id="ref-tsimikas2005" class="csl-entry" role="doc-biblioentry">
Tsimikas, Sotirios, Emmanouil S. Brilakis, Elizabeth R. Miller, Joseph P. McConnell, Ryan J. Lennon, Kenneth S. Kornman, Joseph L. Witztum, and Peter B. Berger. 2005. <span>“Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease.”</span> <em>The New England Journal of Medicine</em> 353 (1): 46–57. <a href="https://doi.org/10.1056/NEJMoa043175">https://doi.org/10.1056/NEJMoa043175</a>.
</div>
<div id="ref-unitedstatessurgeongeneralHealthConsequencesSmoking2014" class="csl-entry" role="doc-biblioentry">
United States Surgeon General. 2014. <span>“The <span>Health Consequences</span> of <span>Smoking</span> – 50 <span>Years</span> of Progress: <span>A Report</span> of the <span>Surgeon General</span>: (510072014-001).”</span> <span>American Psychological Association</span>. <a href="https://doi.org/10.1037/e510072014-001">https://doi.org/10.1037/e510072014-001</a>.
</div>
<div id="ref-societyforvascularsurgerylowerextremityguidelineswritinggroup2015" class="csl-entry" role="doc-biblioentry">
Vascular Surgery Lower Extremity Guidelines Writing Group, Society for, Michael S. Conte, Frank B. Pomposelli, Daniel G. Clair, Patrick J. Geraghty, James F. McKinsey, Joseph L. Mills, et al. 2015. <span>“Society for Vascular Surgery Practice Guidelines for Atherosclerotic Occlusive Disease of the Lower Extremities: Management of Asymptomatic Disease and Claudication.”</span> <em>Journal of Vascular Surgery</em> 61 (3 Suppl): 2S–41S. <a href="https://doi.org/10.1016/j.jvs.2014.12.009">https://doi.org/10.1016/j.jvs.2014.12.009</a>.
</div>
<div id="ref-vogeler2016" class="csl-entry" role="doc-biblioentry">
Vogeler, Tiffany, Claire McClain, and Kirk E. Evoy. 2016. <span>“Combination Bupropion SR and Varenicline for Smoking Cessation: A Systematic Review.”</span> <em>The American Journal of Drug and Alcohol Abuse</em> 42 (2): 129–39. <a href="https://doi.org/10.3109/00952990.2015.1117480">https://doi.org/10.3109/00952990.2015.1117480</a>.
</div>
<div id="ref-ward2019" class="csl-entry" role="doc-biblioentry">
Ward, Natalie C., Gerald F. Watts, and Robert H. Eckel. 2019. <span>“Statin Toxicity.”</span> <em>Circulation Research</em> 124 (2): 328–50. <a href="https://doi.org/10.1161/CIRCRESAHA.118.312782">https://doi.org/10.1161/CIRCRESAHA.118.312782</a>.
</div>
<div id="ref-wattanakit2005" class="csl-entry" role="doc-biblioentry">
Wattanakit, Keattiyoat, Aaron R. Folsom, Elizabeth Selvin, Beth D. Weatherley, James S. Pankow, Frederick L. Brancati, and Alan T. Hirsch. 2005. <span>“Risk Factors for Peripheral Arterial Disease Incidence in Persons with Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study.”</span> <em>Atherosclerosis</em> 180 (2): 389–97. <a href="https://doi.org/10.1016/j.atherosclerosis.2004.11.024">https://doi.org/10.1016/j.atherosclerosis.2004.11.024</a>.
</div>
<div id="ref-witztum1994" class="csl-entry" role="doc-biblioentry">
Witztum, J. L. 1994. <span>“The Oxidation Hypothesis of Atherosclerosis.”</span> <em>Lancet (London, England)</em> 344 (8925): 793–95. <a href="https://doi.org/10.1016/s0140-6736(94)92346-9">https://doi.org/10.1016/s0140-6736(94)92346-9</a>.
</div>
<div id="ref-yaoAnkleSystolicPressure2005" class="csl-entry" role="doc-biblioentry">
Yao, S T, J T Hobbs, and W T Irivne. 2005. <span>“Ankle Systolic Pressure Measurements in Arterial Disease Affecting the Lower Extremities.”</span> <em>British Journal of Surgery</em> 56 (9): 676–79. <a href="https://doi.org/10.1002/bjs.1800560910">https://doi.org/10.1002/bjs.1800560910</a>.
</div>
</div>
</section>
</section>
</section>

</main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    setTimeout(function() {
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      let href = ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const cites = ref.parentNode.getAttribute('data-cites').split(' ');
    tippyHover(ref, function() {
      var popup = window.document.createElement('div');
      cites.forEach(function(cite) {
        var citeDiv = window.document.createElement('div');
        citeDiv.classList.add('hanging-indent');
        citeDiv.classList.add('csl-entry');
        var biblioDiv = window.document.getElementById('ref-' + cite);
        if (biblioDiv) {
          citeDiv.innerHTML = biblioDiv.innerHTML;
        }
        popup.appendChild(citeDiv);
      });
      return popup.innerHTML;
    });
  }
});
</script>
<nav class="page-navigation">
  <div class="nav-page nav-page-previous">
      <a href="./trauma-venous.html" class="pagination-link">
        <i class="bi bi-arrow-left-short"></i> <span class="nav-page-text"><span class="chapter-number">14</span>&nbsp; <span class="chapter-title">Trauma - Venous</span></span>
      </a>          
  </div>
  <div class="nav-page nav-page-next">
      <a href="./clti.html" class="pagination-link">
        <span class="nav-page-text"><span class="chapter-number">16</span>&nbsp; <span class="chapter-title">CLTI</span></span> <i class="bi bi-arrow-right-short"></i>
      </a>
  </div>
</nav>
</div> <!-- /content -->
<footer class="footer">
  <div class="nav-footer">
      <div class="nav-footer-center"><div class="cookie-consent-footer"><a href="#" id="open_preferences_center">Cookie Preferences</a></div></div>
  </div>
</footer>



</body></html>